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T h e  U n i v e r s i t y  o f  U t a h  G r a d u a t e  S c h o o l  
ABSTRACT
 Hydrogen sulfide (H2S) is a toxic gas with a distinct rotten-egg odor.  While the 
detrimental affects of H2S on human health have been known for hundreds of years, it  has 
recently  become apparent that low levels of endogenously produced hydrogen sulfide are 
cytoprotective. In fact hydrogen sulfide is an important signaling molecule in a variety  of 
systems resulting in a large range of physiological effects, from vasodilatory to anti-
inflammatory. However, the exact roles played by  hydrogen sulfide, its concentrations in 
serum and tissues, and the enzymes that produce it  are still being investigated. It seems 
that a lack of tools with which to accurately measure in vivo concentrations of hydrogen 
sulfide has stalled progress in the field. Herein we report several novel, fluorescent 
probes with which to detect endogenous concentrations of hydrogen sulfide both in vitro 
and in biological samples. These probes utilize an arylazide moiety that is selectively 
reduced by hydrogen sulfide to produce a signal. We show that this signal is 
concentration-dependent in a linear manner up  to 300 !M  hydrogen sulfide. We also 
show that these probes are sensitive down to 200 nM  hydrogen sulfide. Additionally, we 
have applied these probes in assays to study hydrogen sulfide-producing enzymes, 
cystathionine "–synthase (CBS), cystathionine #–lysase (CGL), and tryptophan synthase 
(TS). By discovering selective inhibitors of these enzymes, we can modulate hydrogen 
sulfide production in vivo. 
Lastly, we have applied a series of lanthanide-based fluorescent  probes to detect 
hydrogen sulfide in the petrochemical industry. These probes utilize a similar arylazide 
moiety as an antenna. The lanthanide center can be excited after reaction with H2S to give 
a signal with a long lifetime. By  delaying the readout, it is possible to see this signal over 
a highly fluorescent background, such as crude oil. These probes have been used to study 
the presence of hydrogen sulfide in two sour water samples as well as five samples of 
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1.1 Hydrogen Sulfide 
 Hydrogen sulfide (H2S) is a malodorous gas long known for its potent toxicity. In 
1713, a study on the effects of hydrogen sulfide on Italian cesspool workers described 
inflammation of the eyes and eventual blindness.1–3 Five decades later, gases rising from 
the sewers of Paris (later identified as H2S) wreaked havoc among the population. Many 
people suffered the same optic neuritis as the Italian workers with others facing more 
severe reactions: asphyxia and death.2 For over 2 centuries since these incidents, 
hydrogen sulfide was regarded as a noxious, toxic gas.  Therefore, it was surprising when, 
in 1982, it was discovered that human enzymes are capable of producing H2S.4 In 1996 it 
was further suggested that H2S serves as a neuromodulator in the brain.5 Since then, there 
has been an explosion of interest in the potential physiological roles of H2S.   
The work described in this dissertation is centered around the development of 
novel chemical tools for studying enzymatically produced and environmental H2S. In this 
chapter, we will briefly describe the ambiguous physiological effects of endogenous H2S 
and H2S-donating compounds, the probable mechanisms of in vivo H2S production 
(focusing on the enzymatic pathways), and the current detection methods used to study 
H2S. We will also briefly discuss the challenges of detecting H2S in various industrial  
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processes, with an emphasis on the petrochemical industry. First, we will begin with a 
brief discussion on the chemistry of sulfur and sulfide.  
 1.1.1 Chemistry of sulfur and hydrogen sulfide. Sulfur, like oxygen, is a 
chalcogen. However, the two have widely varying chemical reactivities. Because of its 
six valence electrons and empty 3d orbital, sulfur can take on numerous oxidation states 
ranging from (-2) at its most reduced to (+6) at its most oxidized. Additionally, sulfur is 
significantly less electronegative than oxygen, so it does not participate in significant S-
H-S hydrogen bonding,6 making hydrogen sulfide a gas at ambient pressures and 
temperatures and quite lipophilic when fully protonated.  
 Hydrogen sulfide is an example of sulfur in its most reduced form. As such, it is 
nucleophilic, reacting with electrophiles in addition and substitution reactions, reducing 
disulfide bonds, and coordinating to positively charged metal centers.6,7 Hydrogen sulfide 
is also a weak acid. Reported pKa values for the first deprotonation vary slightly between 
6.76 and 7.0, while the second pKa value can range from 12 to 19 depending on 
temperature, pressure, and ionic strength (Figure 1.1).8–12 Under physiological conditions, 
H2S exists mostly in the anionic state, HS-, with approximately 20% present as H2S. It 
should be noted that because of this equilibrium, H2S and hydrogen sulfide in this 
dissertation will refer to all three sulfide species. We will not distinguish between 








Figure 1.1 Dissociation of hydrogen sulfide (H2S). H2S in this work will indicate all 
three species.  
 
 3 
1.2 Hydrogen Sulfide in Human Health 
1.2.1 Physiological effects of hydrogen sulfide. Since its recognition as a 
biologically relevant gas in the 1980s, it has been well accepted that H2S is produced 
endogenously in a myriad of organs where it serves numerous biological functions. 
Though its exact effects are location and concentration dependent, hydrogen sulfide has 
been found to play a variety of physiological roles; however, these roles are somewhat 
incongruous. For example at low micromolar concentrations hydrogen sulfide appears to 
be cytoprotective through upregulation of antioxidant pathways and anti-inflammatory 
genes.13–16 At higher concentrations, hydrogen sulfide is cytotoxic most likely because of 
oxidant generation and glutathione depletion.  
In general, cellular hydrogen sulfide is more often reported as a salutary gas than 
a toxic gas with regard to biology. In section 1.1 we mentioned the discovery of H2S as a 
neuromodulator. Additionally, H2S is neuroprotective in the brain,17–19 and decreased H2S 
levels are associated with neurodegenerative disorders such as Alzheimer’s Disease.20 
Hydrogen sulfide serves as an airway relaxant and anti-inflammatory in the lungs where 
it has been studied in an asthmatic mouse model.15,21–23 Hydrogen sulfide is also a 
regulator of insulin in the pancreas8,24 and is important in mucosal defense and repair in 
the gastrointestinal tract.25–28 The various anti-cancer properties of H2S are still being 
investigated, though the results look promising, particularly in breast and colorectal 
cancers.29–34 One of the most well studied systems with regard to H2S is the 
cardiovascular system where H2S is cytoprotective, vasodilatory, and anti-inflammatory. 
It has been reported that CGL knockout mice are hypertensive and that spontaneously 
hypertensive mice have lower plasma sulfide levels.  Indeed hydrogen sulfide-releasing 
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compounds appear to have antihypertensive activity, underscoring the importance of H2S 
in blood pressure regulation.3,7,9,35–37  
Hydrogen sulfide and its related species are clearly important to human health. By 
elucidating the activities of enzymes capable of producing H2S and the ways in which 
H2S attenuates so many disorders, it may be possible to better understand and treat these 
conditions.  In Chapter 2 of this dissertation, we describe the development of two novel, 
fluorogenic probes for H2S. These probes have utility in studying H2S-producing 
enzymes in vitro as part of a novel assay as described in Chapter 3. This should allow us 
to look for small molecules that can attenuate enzyme activity in vivo. Additionally, these 
probes will also be useful in further studying the release of H2S from small molecule 
sulfide donors (See Chapter 4, for example).  
 1.2.2 Possible reactivity of hydrogen sulfide in vivo. Hydrogen sulfide has a 
plethora of cellular targets as indicated by its widespread physiological effects. While its 
specific molecular targets and pathways are not fully understood and are beyond the 
scope of this dissertation, several general methods by which H2S effects cellular 
processes will be discussed (Figure 1.2).  
As mentioned in section 1.1.1, hydrogen sulfide is nucleophilic. It is therefore 
capable of covalently labeling proteins through addition and substitution reactions. One 
such reaction is the attack by hydrogen sulfide on the porphyrin ring of oxygenated 
hemoglobin, incorporating sulfur into the pyrrole ring.6,38–40 The mechanism and activity 
of this unique molecule and its myoglobin analog have intrigued researchers since their 
discoveries in the late 19th century.38 Another example of the nucleophilicity of hydrogen 



















This reaction is analogous to the nitrosylation of proteins by NO, the predominant 
signaling mechanism for this neuromodulator. In fact, it has been proposed that 
sulfhydration may be more prevalent than nitrosylation and possibly equal in prevalence 
to phosphorylation.41 A recently published study instead suggests that the sulfhydration 
products of cysteine (thiocysteine) and glutathionine (GSSH) may be the reactive species 
responsible for the biological effects attributed to hydrogen sulfide.42,43 Whether these 
 
Figure 1.2 Proposed reactivity and cellular targets of hydrogen sulfide. This figure was 
reprinted with permission from Macmillan Publishers Ltd: Nature Review Drug 
Discovery (Szabó, C. Hydrogen Sulphide and its Therapeutic Potential. Nat. Rev. 





hydropersulfides are formed directly via human enzymes or are reactive intermediates 
resulting from a reaction between biological thiols and enzymatically produced hydrogen 
sulfide remains to be determined. This issue will be further discussed in section 1.2.3. 
In addition to the covalent modification of proteins, hydrogen sulfide can also 
bind to metal centers. Our ability to smell hydrogen sulfide is a result of H2S binding to 
copper-activated olfactory receptors.44,45 Metalloenzymes such as carbonic anhydrase and 
cytochrome c oxidase may also be inhibited by direct binding of H2S.46,47  
Lastly, the reducing power of H2S can be utilized to scavenge reactive oxygen 
species (ROS) and modify enzymes through the reduction of disulfide bonds. Though the 
antioxidant ability of H2S was originally thought to be a major contributor to its anti-
inflammatory effects,48–50 H2S shows little reactivity towards ROS other than HOCl 
under cellular conditions.6,51,52 Therefore, direct radical scavenging by hydrogen sulfide 
most likely plays a minor role in its reported biological effects. However, one could 
postulate that persulfide and polysulfide intermediates may have potential reactivity with 
ROS. Ida et al. suggest that GSSH may have antioxidant potential against hydrogen 
persoxide42 though other ROS were not tested, and the relevance of this reactivity in vivo 
is not known. The redox activities of hydrogen sulfide are more easily seen in disulfide 
bond reduction. It has been proposed that this is the mechanism governing the reversible 
inhibition of sodium channels by H2S.53  The reaction between a disulfide and H2S would 
result in a free thiol in addition to a persulfide. It is possible that the reaction between a 
disulfide such as cystine and H2S would result in thiocysteine, which could then further 
react with other thiols and disulfides.   
 1.2.3 Hydrogen sulfide production in vivo. Given its importance to human health 
 7 
and biology, it is to be expected that the endogenous production and cellular 
manipulation of hydrogen sulfide has been an area of great interest. Despite the intense 
investigation in this area, the major mechanisms of hydrogen sulfide production and even 
the major cellular sources of hydrogen sulfide are still not clear. It has been established 
that endogenous hydrogen sulfide in humans is dependent on three location-dependent 
enzymatic systems:  two pyridoxal 5’-phosphate (PLP)-dependent enzymes, 
cystathionine !–synthase (CBS) and cystathionine "–lyase (CGL), and the coupled 
activities of cysteine aminotransferase (CAT) and 3-mercaptopyruvate sulfurtransferase 
(3-MCT). While the importance of the CAT/3-MCT pathway has recently come to light, 
our focus will be on the two PLP-dependent enzymes CBS and CGL (Figure 1.3).  
Structurally, CBS is a type II-fold, PLP-dependent enzyme consisting of an N-
terminal heme, a highly conserved core, and a C-terminal regulatory domain often 
labeled the CBS domain (Figure 1.4).54–57 Originally studied for its role in homocysteine 
metabolism, CBS catalyzes the first step in the transulfuration pathway. The principal 
reaction catalyzed by CBS is thought to be a beta-replacement reaction between serine 
and homocysteine, producing cystathionine and water in the process (Figure 1.5).58,59 
Replacement of an active site lysine with the amino terminus of an amino acid (serine 
and cysteine are pictured), deprotonation, and elimination of H2X result in the formation 
of an aminoacrylate intermediate.54,56,60–62 Nucleophilic attack by homocysteine (the rate 
determining step for this reaction) on this intermediate produces an external aldimine. 
Elimination of the reaction products and reformation of the Lys-PLP adduct then 
complete the cycle.54,56,59,61,62 The catalytic activity of CBS is enhanced up to three-fold  






















































































































































































































regulatory domain.55,63–66 While not clearly understood, it has been proposed that binding 
of AdoMet induces a conformational change, exposing an active core.63,65 In mutations 
lacking this regulatory domain, a highly active enzyme is formed.58,63  
PLP-dependent enzymes such as CBS appear to be fairly promiscuous. In Chapter 
2, we describe the production of hydrogen sulfide from another type II-fold PLP-
dependent enzyme, tryptophan synthase (TS). This bacterial enzyme catalyzes the last 
step in the synthesis of tryptophan. Although TS is not known to naturally produce H2S, 
TS will catalyze a !-replacement reaction between cysteine and homocysteine under 
optimized assay conditions. Likewise, it has been reported that CBS is capable of 
catalyzing a number of !-replacement reactions (Figure 1.6). For example in addition to 
coupling serine and homocysteine, CBS can also catalyze the reaction between cysteine  
and serine to form lanthionine. However, this reaction is very slow, proceeding at 0.8% 
 
Figure 1.4 Structure of cystathionine !–synthase (CBS) subunit. This figure was 
originally published in the Journal of Biological Chemistry. Edith W. Miles and Jan P. 
Kraus. Cystathionine Beta-Synthase: Structure, Function, Regulation, and Location of 
Homocystinuria-Causing Mutations. J. Biol. Chem. 2004; 279: 29871–29874. © The 



















that of the more traditional reaction.61 Additionally, Ida and coworkers reported the CBS- 
catalyzed conversion of cystine to thiocysteine.42 Again, only a very small turnover was 
detected (1% in 30 min). In general, CBS can catalyze a number of !–replacement 
reactions, but there is little evidence that it is capable of efficiently catalyzing a !– 
elimination reaction67 such as that described by Ida and coworkers. In experiments using 
both yeast extracts containing human CBS and recombinant CBS isolated from E. coli.,  
no elimination of H2S was detected when cysteine was the only substrate present.58 
 


































































































































































































Figure 1.6 Reactions catalyzed by human CBS. Numbers indicate relative efficiency 





















HCl +OH2+ NH3 +
 
Figure 1.6 continued 
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Addition of a thiol such as !-mercaptoethanol (BME) or homocysteine was required. This 
finding fits with the CBS mechanism previously described. Without nucleophilic attack  
on the aminoacrylate intermediate to precipitate release of the product, the reaction is not 
efficient. This may explain the low level of persulfide formation in the presence of 
cystine alone.42 The same trend was also seen in our own experiments with tryptophan 
synthase: the addition of homocysteine greatly improved catalytic turnover over the use 
of cysteine alone. 
It is difficult to speculate which reactions are carried out by CBS and CGL in 
vivo. Most in vitro studies on CBS and CGL require a highly reducing environment, 
while those performed using cystine as the substrate did not. Additionally, it may depend 
on the localization of the enzyme. Cysteine concentrations were found to be 100-fold 
higher than cystine in the cytosol of leukocytes and 10-fold higher in fibroblasts.68 Others 
have reported the reverse in plasma or extracellular fluid.69,70 Using competition 
experiments between cysteine and serine, Chen and coworkers found that preference for 
the !-replacement reaction catalyzed by CBS was extremely dependent on absolute 
substrate concentrations.58 When 10 mM cysteine, serine, and homocysteine were 
present, the amount of cystathionine derived from cysteine and serine reactions was 
nearly equal; however, under 0.1 mM substrate concentration conditions, only 23% of the 
cystathionine produced was a result of cysteine metabolism. Complicating this issue even 
more are the nonenzymatic reactions possible under these conditions. For example it may 
be possible for hydrogen sulfide produced by CBS to interact with thiol substrates such as 
cysteine to form persulfides. Additionally, reports indicating the direct production of 
thiocysteine from CBS and CGL could instead be a result of a small cysteine contaminant 
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being converted into hydrogen sulfide, which then reacts with the cystine to form 
thiocysteine.19   
With so many variables and so many possible reactions, it can be difficult to study 
the activity of CBS in vitro. Since the reactions catalyzed by CBS go through a common 
intermediate and often form cystathionine as a common product, interfering with the 
ability of CBS (or CGL) to catalyze one reaction should inhibit the enzymes’ ability to 
catalyze all reactions. Indeed, the activity of CBS has been traditionally studied using a 
radioactive serine assay in conjugation with homocysteine (Table 1.1). We have seen that 
inhibitors of this reaction (hydroxylamine, HA and aminooxyacetic acid, AOAA) also 
inhibit the production of H2S from CBS in the presence of cysteine and homocysteine. 
While a more detailed comparison of inhibitor potencies for various CBS-catalyzed made 


















reactions is needed, the lack of facile assays for this array of !–replacement reactions has 
has also hampered studies in this area. Once potent (low "M) and selective inhibitors of 
one CBS-catalyzed reaction have been discovered and thoroughly investigated, a more 
detailed study of inhibition under different assay conditions will be in order.  
As mentioned above, only two compounds are routinely used to chemically 
inhibit CBS activity, aminooxyacetic acid (AOAA) and hydroxylamine (HA). These 
compounds target the PLP cofactor of CBS. Therefore, they are not selective for CBS 
over other PLP-dependent enzymes, namely CGL. Potent, selective inhibitors of CBS 
activity would thus have great use in this field and could further our knowledge of 
physiological hydrogen sulfide (either as a free gas or a reactive persulfide intermediate). 
In Chapter 3, our efforts to identify selective CBS activators and inhibitors via enzyme 
activity screens are discussed.  
While it is generally accepted that endogenous hydrogen sulfide production is 
dependent on the three enzymatic pathways just described, it is not clear if this H2S is 
immediately released or if it is instead stored until a physiological event triggers its 
release.  Indeed two types of sulfur stores are known: acid-labile sulfur stores and 
reduction-labile sulfur stores. Acid-labile sulfur pools can be found in mitochondria and 
most likely take the shape of metal-sulfide clusters.19,77 However, because mitochondria 
are not acidic, these pools may or may not have physiological relevance. Therefore, 
reduction-labile sulfur pools may be the dominant source of stored sulfur in cells.  
Indeed, Ishigami and coworkers have reported that exogenously applied Na2S was readily 
absorbed by heart, liver, and brain homogenates and that this increased reduction-labile 
sulfur stores without affecting the quantity of acid-labile sulfur.18 Additionally, it has 
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been hypothesized that persulfides and polysulfides may serve as the source of this 
reduction-labile sulfur.78–89 Low molecular weight persulfides have biological 
importance. They are capable of easily transferring a terminal sulfur to protein thiols such 
as cysteine to form new persulfides. This transfer may be more readily controlled than 
free sulfide (H2S). Additionally, these newly modified proteins often exhibit altered 
activity from their unmodified forms (that is, persulfide modifications can often activate 
or inhibit enzyme activity) or these proteins can be “carrier proteins” further modifying 
tRNA or serving as sulfur sources for the synthesis of sulfur-containing cofactors and 
vitamins. As a chemical model for persulfide reactivity, Bailey and coworkers 
synthesized and fully characterized the hydropersulfide tritylhydrodisulfide (TrtSSH) and 
found that TrtSSH could be reduced in organic solvent to from the thiol TrtSH and 
sulfide.90 Thus it is possible that, rather than immediately reacting, endogenously 
produced H2S could be oxidized into persulfide or polysulfide complexes that can either 
react directly with protein targets42 or can be rereduced to liberate hydrogen sulfide when 
needed.18 Another hypothesis is that, as mentioned above, the H2S-producing enzymes 
CBS and CGL catalyze the direct synthesize of persulfides (from sources such as cystine) 
in addition to free H2S (from cysteine and homocysteine). These persulfides could then 
either react with molecular targets, transferring a terminal sulfur in the process, or they 
could release H2S under reducing conditions. It is not clear which reactive sulfur species 
is produced most abundantly in vivo nor which species is responsible for the reported 
biological effects of H2S: persulfides, hydrogen sulfide, acid-labile sulfur pools, or an as-
yet undiscovered sulfide containing species. It is also yet to be determined which, if any, 
of the H2S-detection methods (described in more detail in section 1.3 and Chapter 2) are 
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selective for unbound H2S over persulfide complexes.  
1.2.4 H2S-donating compounds. Because of the interest in understanding 
endogenous hydrogen sulfide and activated sulfur compounds, a variety of small 
molecules capable of modifying H2S levels have been identified.  These compounds 
typically use one of two methods: some compounds affect H2S-producing enzyme 
activity as just discussed while others are metabolized to release H2S directly. Many of 
these H2S-donating compounds can be found in nature. For example, the health benefits 
of garlic consumption have long been known.91–95 Is has been postulated that these 
antioxidatant and cardioprotective effects are a result of H2S-release from a garlic 
metabolite, diallyl disulfide (DADS) (Figure 1.7), which produces H2S in the presence of 
glutathione.10,32,34,96 It is also possible that DADS could produce an active GSSH 
complex that is detected as H2S in reducing environments. Another H2S-donating 
compound found in garlic, S-allyl cysteine (SAC), has inspired a number of derivatives. 
These compounds are metabolized by CGL to form H2S and appear to greatly effect the 
cardiovascular system.7,34,96,97  
In addition to these naturally occurring compounds, synthetic H2S-donating 
agents are also known. One of the most promising (and therefore well studied) is anethole 
dithiolethione, ADT (Figure 1.7). ADT has been conjugated to known therapeutics, often 
















Figure 1.7 H2S-donating compounds. 
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approach is that the H2S release will attenuate the gastrointestinal tract inflammation and 
damage caused by routine consumption of these drugs.  
H2S-donating compounds show promise as potential therapeutics and will aid in 
elucidating the roles of H2S in human health; however, more studies need to be done on 
these compounds. The mechanism and especially rate of H2S release for many of these 
compounds is not well understood. It has been suggested by some that several of these 
compounds may have biological activity independent of H2S release. In Chapter 4, we 
discuss a new H2S-donating compound and compare its reactivity and rate of H2S release 
to two known H2S-producing agents.  
 
1.3 Current Detection Methods for Hydrogen Sulfide 
 Hydrogen sulfide is clearly an important molecule in a variety of settings; 
however, a lack of suitable detection methods has slowed the exploration of this field. For 
example, controversial endogenous H2S concentrations in plasma and tissues are most 
likely a result of insufficient or interfering H2S-detection techniques.  
 1.3.1 Traditional detection methods. Other than the human nose, which loses its 
ability to detect H2S concentrations at 50–100 ppm,9 the oldest detection method for 
hydrogen sulfide dates back to the 19th century. The methylene blue assay (Figure 1.8) 
couples two equivalents of 4-aminodimethylaniline and sulfide in the presence of zinc, 
ferric chloride, and strong acid to produce an aromatic compound with a signature blue 
color.76 While this reaction is somewhat selective for H2S (in our hands a pink color 
forms in the presence of some thiols such as !–mercaptoethanol, BME), it may not be 










reported;3,10,11,15,18,62,97 these pools are likely to release sulfide under the methylene blue 
assay conditions, giving a higher experimental concentration than actually exists. 
Additionally, these conditions could cause sulfide release from enzyme cofactors and 
other stable sulfur sources. It may be surprising then that methylene blue appears to be 
the assay of choice for many biologists.  
 The frequently used standard in the field for the petrochemical and water 
treatment industries is even more rudimentary. In these fields, the presence of sulfide is 
determined qualitatively using lead acetate. The presence of lead sulfide as a precipitant 
is indicative of H2S. Additionally, gas chromatography98 and the sulfide ion selective 
electrode99 are also employed.  
 1.3.2 Colorimetric detection methods. Aside from the methylene blue assay, few 
colorimetric tests for H2S are readily available. These assays should have the advantage 
that they provide an easy readout without the need for costly and bulky equipment; 
however, they are often not as sensitive as their fluorogenic counterparts. A novel 

























Figure 1.8 Colorimetric hydrogen sulfide detection methods. a) methylene blue  





benzoxadiazole-derivates as the H2S sensor (Figure 1.8). Upon nucleophilic substitution 
by H2S, the solution becomes pink. The mechanism of this probe is somewhat limiting. 
An excess of H2S is required to form the pink product since an intermediate is formed 
when less than one equivalent is added.  
 1.3.3 Fluorescent detection methods. Thanks to the intense interest in studying 
physiological hydrogen sulfide, a number of fluorescent probes were developed in the 
last few years.100–105 These probes frequently fall into one of several categories: probes 
that are reduced by H2S, probes that undergo nucleophilic attack by H2S, and metal-based 
probes.  
In 2011, the He lab developed a novel fluorescent probe containing two proximal 
electrophilic moieties (Figure 1.9).106  This allows for some selectivity as competing 
thiols can react with one but not both groups. However, this also means that these thiols 
can reversibly inhibit hydrogen sulfide from binding, reducing the signal in high thiol 
backgrounds.  
Another commonly employed motif in the detection of H2S has been the use of 
aryl nitrites and azides. Hydrogen sulfide selectively reduces these moieties to form the 
amine derivatives. For example, the Pluth group developed nitrite (HSN1) and azide 
(HSN2) derivatives of amino-naphthaline (Figure 1.9).104 While HSN1 and HSN2 
possess little background fluorescence, the amine product, which forms upon reaction 
with H2S, is highly fluorescent. As the reduction of nitrite groups is not as selective, 
HSN1 has a large background in the presence of two biologically relevant thiols, 
glutathione and cysteine. These probes are also limited to H2S concentrations greater than 











































Figure 1.9 Fluorescent H2S-selective probes. a) An example of a probe that undergoes 
nucleophilic attack by H2S. b) Nitrite and azide probes are reduced by H2S to form 
amines. c) A metal based probe eliminates a 7-mercapto-4-methylcoumarin in the 







Lastly, thiophillic metals have also been used as tools to detect H2S. The 
Galardon lab developed a zinc-based sensor utilizing a coumarin scaffold in 2009 (Figure 
1.9).107 Upon exposure to H2S, the coumarin is displaced, theoretically resulting in a 
fluorescent signal. Curiously, this is a “turn-off” sensor with the fluorescence diminishing 
with increasing H2S. A maximum detection limit of 80 !M is seen before the signal 
completely diminishes.  
 For utility in biological systems and applications, a fluorescent H2S-selective 
probe should possess several properties. It should be selective for H2S over other thiols, 
reducing agents, and enzyme cofactors; it should give a quick, “turn-on” response to 
detect H2S in real time; it should have a large detection range; and it should be sensitive 
to low levels ( < 1 !M ) of H2S. We have developed novel probes to detect H2S under 
physiologically relevant conditions, as described in Chapter 2. In addition, fluorogenic 
and colorimetric probes compatible with industrial applications are described in Chapter 
5.  
 
1.4 Hydrogen Sulfide as an Environmental Pollutant 
 In addition to its potential roles in biology and medicine, hydrogen sulfide is also 
a major player in various industries such as tanneries, paper milling, water treatment, and 
oil refining. In the latter industry, especially, hydrogen sulfide poses a major challenge. 
H2S, soluble in both oil and water, must be identified, removed, and processed. 
 Crude oil is formed by the putrefaction of algae and zooplankton at high 
temperatures (65–150 ˚C) and pressures over long periods of time (~10 million years).108 
Because sulfur-containing amino acids and biological molecules are broken down, 
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hydrogen sulfide is often formed. If a crude oil sample contains low sulfide levels 
(>0.42%) the oil is deemed sweet; however, if higher levels of sulfides are found, the oil 
is deemed sour. During the processing of oil, the oil goes through a number of processes 
(distillation, desalting, alkylation, hydrocracking, etc.) where it comes into contact with 
water. This eventually removes the hydrogen sulfide from the oil, but creates problematic 
sour water.109 With exceptionally high levels of H2S, NH3, aromatics, and other 
contaminants, sour water must be purified before it can be released into the environment 
or reused in the refinery. This is accomplished by running the sour water through a 
stripper which strips out all the contaminants.  The water is then reused in the factory 
while the sulfur is often sold as sulfur cakes or further oxidized to form sulfuric acid.  
 Because hydrogen sulfide is corrosive and an environmental toxin, the 
Environmental Protection Agency (EPA) has set limits on the concentration of H2S that 
can be released in water or sold in gasoline. Hydrogen sulfide in wastewater must be 
below the subjective olfactory detection limit, while that in oil is regulated to no more 
than 15 ppm.110 Therefore, the monitoring of H2S throughout the oil refining processing 
is of great importance. With highly fluorescent hydrocarbon contaminants and dark oils, 
traditional fluorescent and colorimetric detection methods often fail; however, in Chapter 
5 we discuss a series of lanthanide-based probes capable of detecting H2S in high 
background environments.  
 
1.5 Concluding Remarks 
 Over the last 4 decades, our perception of hydrogen sulfide has shifted from 
viewing it as a toxic gas and environmental hazard to an essential signaling molecule. 
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While much is known about its broad physiological effects, much remains to be learned 
about its exact mechanisms of action and potential reactive intermediates. Selective H2S 
detection methods compatible with biological systems and industrial samples would 
greatly aid in this endeavor. Additionally, selective chemical probes with which to 
mediate H2S-producing enzyme activity would allow for further investigations into the 
specific roles of CBS and CGL in vivo. In this work, we have focused on developing new 
chemical tools with which to better study hydrogen sulfide and the enzymes capable of 
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AZIDOCOUMARIN COMPLEXES AS NOVEL PROBES  
FOR HYDROGEN SULFIDE * 
 
2.1 Introduction 
 Hydrogen sulfide (H2S) is a flammable gas, notorious for its distinct rotten egg-
like odor and potent toxicity. While the majority of studies on the subject prior to the 
early 1980s focused on the negative health effects of H2S and those who work around it,1–
3 it has more recently come to light that this toxic small molecule or its downstream 
products are also important in cellular signaling and serve beneficial purposes in the 
inflammatory, cardiovascular, and nervous systems.4–7 The majority endogenous 
hydrogen sulfide is dependent upon two human enzymes, cystathionine !–synthase 
(CBS) and cystathionine "–lysase (CGL). Though it is clear that H2S plays critical roles 
in human physiology, the exact roles, pathways, and even concentrations of H2S are still 
unclear.8–11   
 One challenge that has dramatically slowed the advancement of this field is the 
lack of chemical probes with which to study H2S in biological systems. While many 
colorimetric12–14 and fluorescent9,15–18 probes have recently flooded the field, few have  
                                                
* This chapter in an adaptation of both published work37 and a manuscript recently 
accepted for publication.43 
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the sensitivity, 9,17 selectivity,9 linear response,19 or reaction speed19 that is required for 
utility either as part of an enzyme assay or in high throughput settings. With the aim of 
meeting this challenge, we report the synthesis and characterization of two H2S-
responsive probes, AzMC and AzCC.  
 
2.2 Materials and Methods  
2.2.1 General considerations. All chemicals were purchased from commercial 
sources and used as received unless indicated otherwise. AzMC produced in our lab is 
now available from Sigma Aldrich (product number L511455) and Echelon Biosciences, 
Inc., Salt Lake City (product number D-0010). The truncated CBS enzyme (residues 1-
413, CBS !1-413) was expressed in the Kraus lab as reported previously.20 Tryptophan 
synthase was purchased from Sigma Aldrich. The 1H  and 13C NMR data were collected 
on a Varian 400 MHz NMR spectrometer. Chemical shifts are reported in parts per 
million referenced to internal standard TMS = 0.00 ppm). Fluorescence and UV/Vis data 
were collected on a Molecular Devices Spectra Max M5. 
2.2.2 Synthesis of 7-azido-4-methylcoumarin, AzMC. Precautions were taken to 
reduce the amount of light in the reaction. Foil was used to cover the flask, a septum was 
used to cover the mouth of the flask, and the hood lights were turned off. 7-amino-4-
methylcoumarin (0.5 g, 1 equiv) was placed in water (11 mL) and allowed to stir at 0 °C 
in an ice/water bath. Concentrated sulfuric acid (3 mL) was added to the reaction in a 
dropwise fashion to maintain the temperature. Sodium nitrate (0.25 g, 1.2 equiv) was 
dissolved in water (3.4 mL), cooled to 0 °C, and added in a dropwise fashion to the 
reaction over 30 min. The mixture was then allowed to stir at 0 °C for 1 h. Meanwhile, 
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sodium azide (0.33 g, 1.76 equiv) was dissolved in water (2 mL) and cooled to 0 °C. 
After 1 h, the sodium azide solution was added to the reaction mixture in a dropwise 
fashion, and the formation of an off-white precipitate was immediately observed. The 
reaction mixture was then allowed to warm to room temperature overnight with stirring, 
and the solid was collected using a frit, washed with water (100 mL) and briefly air-dried. 
The resulting solid was then dissolved in chloroform, dried over anhydrous magnesium 
sulfate, and filtered, and the solvent was removed to yield a brown powder in 74.5% yield 
(0.44 g). 1H NMR (!, (CD3)2SO) 2.41 (s, 3H), 6.33 (s, 1H), 7.15 (m, 2H), 7.77 (d, 1H). 
13C NMR (!, (CD3)2SO) 17.97, 106.64, 113.08, 115.39, 116.61, 126.82, 143.13, 152.76, 
153.89, 159.39 
2.2.3 Synthesis of ethyl (3-hydroxyphenyl)carbamate,1. The commercial 3-
aminophenol was recrystallized from hot water and again from hot toluene prior to use. 
Compounds 1, 2, and ACC were prepared using a modification of a previously published 
procedure.21 An aliquot of 3-aminophenol (10 g, 1.0 equiv) in 35 mL ethyl acetate was 
refluxed for 30 min. Ethyl chloroformate (6.2 mL, 0.7 equiv) was added slowly over 30 
min, resulting in the precipitation of a white solid. The reaction was refluxed 1 h longer. 
The precipitate was removed by vacuum filtration and washed with 2 x 3 mL ethyl 
acetate. The amber filtrate was concentrated under vacuum, and the product was 
recrystallized from hot isopropanol to give a white crystalline product in 41% yield (4.8 
g). 1H NMR (!, (CD3)2SO) 1.23 (t, 3H), 4.11 (q, 2H), 6.38 (d, 1H), 6.86 (d, 1H), 6.99-
7.03 (m, 2H), 9.31 (s, 1H), 9.47 (s, 1H). 
2.2.4 Synthesis of 7-N-(carbethoxy)aminocoumarin-4-acetic acid, 2. Ethyl (3-
hydroxyphenyl)carbamate (1) (1.0 g, 1.0 equiv) was suspended in 22 mL of concentrated 
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H2SO4 at 0 °C. An aliquot of 1,3-acetone-dicarboxylic acid (0.9 g, 1.1 equiv) was added 
in three portions, and the mixture was allowed to warm to room temperature overnight. 
The resulting red-brown solution was poured over 33 g ice and stirred for 30 min. A 
cream-colored solid was collected by vacuum filtration, washed with 3 x 16 mL diethyl 
ether, and recrystallized from hot acetonitrile, yielding 1.5 g of product (89% yield). 1H 
NMR (!, (CD3)2SO) 1.26 (t, 3H), 3.85 (s, 2H), 4.16 (q, 2H), 6.32 (s, 1H), 7.37 (d, 1H), 
7.39-7.61 (m, 2H), 10.16 (s, 1H).  
2.2.5 Synthesis of 7-amino-4-carbamoylmethylcoumarin, ACC. A 4 g aliquot (1 
equiv) of 7-N-(Carbethoxy)aminocoumarin-4-acetic acid (2) was dissolved in 4 M 
sodium hydroxide (44 mL) and refluxed overnight. After cooling, the pH was adjusted to 
2 using sulfuric acid, and the mixture was cooled to 4 °C. The resulting golden flaky 
precipitate was collected by vacuum filtration. Although the product was too wet to 
determine an accurate yield, it was carried on to the next step. 1H NMR (!, (CD3)2SO) 
3.73 (s, 2H), 5.98 (s, 1H), 6.17 (s, 2H), 6.42 (d, 1H), 6.56 (dd, 1H), 7.32 (d, 1H), 12.67 (s, 
1H). 
2.2.6 Synthesis of 7-azido-4-carbamoylmethylcoumarin, AzCC. 7-amino-4-
carbamoylmethylcoumarin (3) (3.4 g, 1.0 equiv) was suspended in water (72 mL) at 0 °C 
followed by careful addition of 26 mL of concentrated H2SO4. A cold solution of sodium 
nitrite (1.3 g, 1.2 equiv) in 22 mL water was added in a dropwise fashion, and the 
solution was allowed to stir for 1 h at 0 °C. A cold solution of sodium azide (1.7 g, 1.7 
equiv) in 13 mL water was added in a dropwise fashion, resulting in the immediate 
formation of a precipitate. The reaction was allowed to stir overnight, warming to room 
temperature. The brown-red solid was collected, washed with water, dissolved in 
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chloroform, and filtered again. The filtrate was dried over MgSO4 and gravity filtered, 
and the solvent removed under vacuum to give 0.5 g of the final product (14% yield over 
two steps). 1H NMR (!, (CD3)2SO) 3.91 (s, 2H), 6.44 (s, 1H), 7.15 (d, 1H), 7.18 (s, 1H), 
7.71 (d, 1H).  
2.2.7 AzMC as a sensitive probe for hydrogen sulfide. Sodium hydrogen sulfide 
was used as a convenient, readily measurable source of sulfide for these experiments. All 
fluorescence studies were carried out using 190 µL activity buffer (200 mM Tris HCl pH 
8.0, 5 µM pyridoxal 5ʼ-phosphate, 10 mM glutathione, 0.5 mg/mL BSA) and 10 µL 
DMSO, which was used to dissolved the 7-azido-4-methylcoumarin, unless otherwise 
specified. The probe was excited at 365 nm, and emission spectra at 450 nM were taken 1 
h after mixing. A probe concentration of 10 µM was used while NaHS concentrations 
varied from 100 nM to 400 "M. 
2.2.8 AzMC as a selective probe for hydrogen sulfide. A 10"M AzMC solution in 
buffer (5% DMSO was used to dissolve AzMC) was tested against a variety of thiols and 
reducing agents to determine selectivity for H2S. AzMC was tested alone and in the 
presence of 100 "M NaHS, 10 mM- 30 mM cysteine, 10 mM- 30mM homocysteine, 1 
mM PLP, 1 mM AdoMet, 100 "M- 1mM DTT, 100 "M- 1 mM TCEP, 10 mM 
glutathionine, and 10 mM BME.  
2.2.9 AzCC as a hydrogen sulfide probe.  As with AzMC, all fluorescence studies 
were carried out using 190 µL activity buffer (200 mM Tris HCl pH 8.0, 5 µM pyridoxal 
5ʼ-phosphate, 10 mM glutathione, 0.5 mg/mL BSA) and 10 µL DMSO, which was used 
to dissolve the AzCC, unless otherwise specified. The probe was excited at 365 nm, and 
emission spectra at 450 nM were taken 1 h after mixing. A probe concentration of 10 µM 
 36 
was used while NaHS concentrations varied from 25 to 300 !M. 
2.2.10 !1-413 CBS enzyme activity assay using AzMC. Truncated CBS activity 
studies were carried out in 190 µL activity buffer and 10 µL DMSO, which was used to 
dissolve the 7-azido-4-methylcoumarin. The probe concentration was 10 µM, the cysteine 
and homocysteine concentrations were each 2.5 mM, and 0.25 !g of CBS "1-413 (a final 
concentration of 27.8 nM) was used in a total volume of 200 !L. Immediately following 
the addition of substrates, the fluorescence of the mixture at 450 nm (#ex = 365 nm) was 
monitored for 1 h. The plate reader was set up to automatically shake the plate for 30 s 
prior to the first data point and for 5 s between each data point (every min). 
2.2.11 Detection of CBS activity in crude cell extract using AzMC. Three CBS 
mutations in bacterial cell extracts were obtained from the Kraus lab at UC-Denver. A 2.5 
!g aliquot of protein was used in each experiment with 2.5 mM cysteine, 2.5 mM 
homocysteien, and 10 !M AzMC. (Indicated experiments contained 300 !M AdoMet.) 
The buffer consisted of 200 mM Tris, 0.5 mg/ml BSA, 5 !M PLP, 10 mM GSH, pH 8.0. 
The DMSO concentration was held constant at 5% total volume.  
2.2.12 Cystathionine beta-synthase (CBS) enzyme activity assay using AzMC or 
AzCC. Both azidocoumarin probes were validated as assays to measure the activity of 
wild type human CBS. Several concentrations of CBS (0.25–5 !g) were tested against 10 
!M probe, 2.5 mM cysteine, and 2.5 mM homocysteine in 190 !L buffer and 10 !L 
DMSO.  
2.2.13 Cystathionine gamma-lyase (CGL) enzyme activity assay using AzMC. 
Experiments to monitor H2S production by CGL were carried out in 190 µL activity 
buffer with 10 µL DMSO used to dissolve the AzMC (10 !M). Cysteine and 
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homocysteine concentrations were each 2.5 mM, and 5 !g of CGL was used in a total 
volume of 200 !L. Immediately following the addition of substrates, the fluorescence of 
the mixture at 450 nm ("ex = 365 nm) was monitored for 1 h. The plate reader was set up 
to automatically shake the plate for 30 s prior to the first data point and for 5 s between 
each data point (every min). 
2.2.14 Tryptophan synthase (TS) enzyme activity assay using AzMC. Experiments 
to monitor H2S production by TS were carried out in 190 µL activity buffer with 10 µL 
DMSO used to dissolve AzMC. The probe concentration was 10 µM, the cysteine and 
homocysteine concentrations were each 10 mM and 20 !g of TS was used in a total 
volume of 200 !L. The probe was excited at 365 nm, and emission spectra at 450 nM 
were taken 1 h after mixing. 
 
2.3 7-Azido-4-Methylcoumarin (AzMC) 
Having experience with the coumarin scaffold,22–26 we chose to base our work on 
the known fluorescent compound 7-amino-4-methylcoumain (AMC).27–29 This 
fluorophore has been used extensively in enzyme assays and has been validated for use in 
such systems.27 It has previously been established that aryl azides are readily reduced by 
hydrogen sulfide to form the amine.16,18 We therefore hypothesized that azide derivatives 
of AMC, AzMC and AzCC, may have use as probes for H2S.   
2.3.1 Design and synthesis of AzMC. AzMC was synthesized using a modification 
of a previously reported procedure.28 After reaction of AMC with sodium nitrite for 1 h in 
acid, the aryl azide was formed overnight using sodium azide. Unlike the amine and nitro 
derivatives, the azide is poorly soluble in acidic aqueous solution and readily precipitates 
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as it is formed. The product can then be collected by filtration and dried to give pure 
AzMC.   
2.3.2 Reactivity: sensitivity and selectivity. With the goal of obtaining a facile 
fluorogenic assay for H2S that can be used as a chemical probe of H2S production, we 
had several specific properties in mind (Table 2.1). First, we required a probe with a 
broad linear range since serial dilutions could lead to increased errors and may not be 
practical in high throughput settings. We also required a probe sensitive enough to detect 
low levels of H2S. While micromolar extracellular H2S levels have been reported,10,30–32 it  
has been theorized that these concentrations could be grossly inflated. In fact, it has been 
proposed that H2S levels in tissues may be as low as 15 nM.10,32,33 Lastly, we required a 
probe capable of detecting H2S in the presence of much higher concentrations of other 
biologically relevant thiols, reducing agents, and enzyme cofactors.  
We began our investigation into AzMC by studying its reactivity with NaHS, a 
commonly used source of H2S.34 In contrast to the parent compound AMC, AzMC is 
minimally fluorescent. Upon reaction with NaHS, AzMC is reduced to form AMC with a 








Table 2.1 Desirable Qualities in a H2S-Probe with Utility in Enzyme Assays 
 
• Fluorescent 
• Selective for H2S over other thiols and possible assay components 
• Linear response to H2S over a broad range (at least 1–100 µM) 
• Sensitive to H2S: capable of detecting < 1 µM 
• Fast acting, in that H2S can be detected in real time 


















NaHS concentrations ranging from 200 nM to 100 !M NaHS and is an ideal dynamic  
range for enzyme assays and biological applications. These values are also to be expected 
as they are inline with those previously reported for other azide-based H2S probes,16 
including AzMC.28  
 We next explored the selectivity of AzMC for H2S over other thiols, reducing 
agents, and enzyme cofactors. As indicated in Figure 2.2, there was no response to 10 
mM cysteine or homocysteine, 1 mM pyridoxial 5’-phosphate (PLP, the cofactor for CBS  
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Figure 2.1 Synthesis and reactivity of AzMC. a) Synthetic scheme of AzMC. AzMC is 
reduced to AMC upon reaction with  H2S. b) Reduction of 10 !M AzMC with NaHS 


















and CGL) or 1 mM S-adenosyl-L-methionine (AdoMet), the allosteric activator of human 
CBS, though dithiothreitol (DTT) and tris(2-carboxyethyl)phosphine (TCEP) (common  
reducing agents with large negative reduction potentials) were capable of reducing 
AzMC. Two other reducing agents, glutathione and !-mercaptoethanol, (with smaller 
negative reduction potentials) did not interfere. Thus, while AzMC does not display 
absolute selectivity for H2S, it does display enough selectivity to have utility in enzyme 
assays and biological samples provided care is taken to avoid DTT and TCEP.  
Lastly, we explored the pH dependence of the AzMC reduction. While the 
background fluorescence of AzMC remained constant, over the range of pH tested (6.0–
8.0), the reaction of AzMC with NaHS and AzMC with cysteine increased with 
 
Figure 2.2 Selectivity of AzMC. a) AzMC is selective for H2S in activity buffer.  
















































































































increasing pH. A maximum difference between the response for NaHS over cysteine was 
seen at pH 6.5; however, the maximum activity of CBS is reached at pH 8.0. Therefore, 
this pH was used for all experiments. 
 Because of the usefulness of AzMC for detecting hydrogen sulfide, AzMC 
synthesized in our lab is now commercially available through both Sigma Aldrich and 
Echelon, Inc. AzMC is doing quite well and is already profitable.  
 
2.4 7-Azido-4-Carbamoylmethylcoumarin (AzCC) 
2.4.1 Design and synthesis. Like AzMC, AzCC was also designed after AMC. 
However, by replacing the methyl at the 4-position with a carboxylic acid, we were able 
to instill AzCC with improved solubility in aqueous solutions. It has been shown that 
cystathionine !-lysase35 and I278T CBS36, the most common missense CBS mutation, are 
sensitive to DMSO, and the sensitivity of CBS and CGL to high DMSO concentrations 
was, indeed, confirmed in our lab. It was, therefore, desirable to design a more soluble 
probe for use in such situations. Additionally, the carboxylic acid moiety could allow for 
conjugation with targeting agents such as peptides. 
 ACC was synthesized as described previously.28 Briefly, 3-aminophenol was 
purified then reacted with ethyl chloroformate prior to a Pechmann condensation reaction 
to form the coumarin. After deprotection, the azide was formed from the amine as shown 
in Figure 2.3.37  
2.4.2 Reactivity of AzCC. The reactivity of AzCC was studied using analogous 
approaches to those employed in the study of AzMC. It was determined that, like AzMC,  












was seen, and, in fact, nearly identical fluorescent signals were produced (Figure 2.4).  
 
 2.5 Azidocoumarin Hydrogen Sulfide-Probes in Biological 
Conditions 
The newly synthesized azidocoumarin probes should have many uses in 
biological studies. To validate these probes further, AzMC was tested under biological 
conditions (serum and crude bacterial extracts). Additionally, both probes were used in 
assays to study purified enzyme activity. 
2.5.1 Selectivity of AzMC in human serum. In addition to studying the reactivity of 
AzMC with NaHS and other biologically relevant thiols in buffer, we were also interested 
in determining the selectivity of AzMC for H2S in human serum. We found the 
selectivity of AzMC to be consistent no matter the media (Figure 2.2).  
2.5.2 Detection of purified enzyme activity using azidocoumarin probes. With two  
 
Figure 2.3 Syntheses of ACC and AzCC. 
  


















































H2S-selective probes in hand, we set about designing an assay for H2S-producing 
enzymes. By limiting the concentration of PLP (which quenches AMC) in the buffer and 
utilizing glutathione as the reducing agent, we were able to design an assay capable of 
detecting the release of H2S from enzymes in real time (Figure 2.5).  
 For simplicity, we began these studies by using a truncated version of human 
CBS, CBS !1-413, that does not contain the AdoMet-binding regulatory domain and has 
high constitutive activity in the absence of an activator.20 As shown in Figure 2.5, 
significant signal over the background was recorded for CBS !1-413 activity using 
AzMC as the probe in the presence of cysteine and homocysteine. We then applied this 
assay to two other enzymes, the H2S-producing enzyme CGL and tryptophan synthase 
(TS). TS is the prototypical type II fold PLP-dependent enzyme. In fact, TS shares the 
same highly conserved region as CBS, showing 28.5% sequence identity and 36% overall 
similarity.38 While TS is known to catalyze the synthesis of tryptophan from serine and  
 
Figure 2.4 Response of 10 "M AzMC and 10 "M AzCC to NaHS. The reactivity of 







































indole in bacteria, yeasts, molds, and plants,39 it had been shown that TS is capable of 
catalyzing a !-elimination reaction on cysteine to release H2S.40 Indeed, we were able to 
monitor the activity of both CGL and TS using AzMC in the presence of cysteine and 
homocysteine (Figure 2.5). Additionally, while the evolution of H2S can be observed 
from TS in the presence of cysteine alone, the addition of homocysteine promotes the 
reaction, likely by reacting with the "-aminoacrylate intermediate formed upon release of 
H2S to form cystathionine and thereby promoting catalytic turnover of the enzyme.  
 Lastly, we investigated the full length (WT) human CBS enzyme using AzCC. 
 
Figure 2.5 Azidocoumarins as tools to study enzyme activity. a) General enzyme 
assay scheme. b) AzMC (10 #M) as a tool for studying CBS $1-413 (5 #g), CGL (5 


























































While this enzyme is less active than the truncated mutant, activity was seen both with 
and without 300 !M AdoMet. Additionally, we saw a roughly two-fold increase in 
activity when AdoMet was present.  
2.5.3 Detecting CBS activity in crude bacterial cell extract. In addition to purified 
enzyme, we are also interested in testing for low levels of endogenous CBS activity. 
Deactivating CBS mutations41,42 can be a cause of homocystinuria (see Chapter 3). It is 
possible that our newly developed assay could be used to diagnose this genetic disorder 
in patient samples by determining the activity level of CBS.  
After obtaining three samples containing distinct CBS mutants in crude bacterial 
extracts from the Kraus laboratory at the University of Colorado-Denver, we attempted to 
monitor CBS activity and its responsiveness to AdoMet using the AzMC assay (Figure 













Figure 2.6 AzMC (10 !M) as a tool for studying CBS activity in crude bacterial cell 
extract (2.5 !g protein). CBS-522 and CBS-526 are AdoMet-responsive mutations, 
while CBS-39 is AdoMet-unresponsive—the addition of AdoMet does not appear to 


































we were still able to see enzyme activity over background under our assay conditions. 
Additionally, we detected increased activity levels in the presence of 300 !M AdoMet for 
the CBS-522 and CBS-526 mutations. Indeed these mutations were confirmed as 
AdoMet-responsive mutations using a radioactive serine-based assay, while CBS-39 was 
found to be AdoMet-unresponsive. These findings further validate AzMC and AzCC, not 
only as H2S-selective probes, but additionally as tools with which to study enzyme 
activity.   
 
2.6 Conclusion 
 We have designed and synthesized two hydrogen sulfide-selective probes based 
on the commonly used fluorophore AMC, AzMC and AzCC. These probes show 
selectivity for NaHS over other thiols (cysteine, homocysteine, glutationine, and "-
mercaptoethanol), are sensitive to nanomolar concentrations of NaHS, and can be utilized 
over a range of pH conditions. Additionally, these probes can be used to provide a facile, 
sensitive, direct, and continuous assay for monitoring the activity of H2S-producing 
enzymes, specifically CBS, CGL, and TS, both in buffer with purified enzyme and in 
crude cellular extracts. These probes may have utility in enzyme assay screens as we 
have shown that they are compatible under enzyme assay conditions. They may also have 
utility in industrial settings where the need for H2S-detecting technology is great.  
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IDENTIFICATION OF CYSTATHIONINE !–SYNTHASE  
INHIBITORS USING A HYDROGEN SULFIDE  
SELECTIVE PROBE * 
 
3.1 Introduction 
 In Chapter 2 we discussed the design, synthesis, characterization, and 
investigation of two azidocoumarin complexes, AzMC and AzCC. These complexes have 
utility not only as sensors for low to moderate hydrogen sulfide (H2S) levels but, 
additionally, as tools with which to monitor the activity of enzymes capable of producing 
H2S: cystathionine !–synthase (CBS), cystathionine "–lyase (CGL), and tryptophan 
synthase (TS).1,2 CBS is of special interest because of the important roles it plays in 
human health. In addition to potential hydrogen sulfide production in vivo, it has been 
shown that CBS is the primary enzyme responsible for the regulation and metabolism of 
homocysteine, a toxic small molecule, in the brain and central nervous system.3–7 
Hyperhomocysteinemia, elevated serum homocysteine levels, has been associated with 
cardiovascular disease,8–11 thrombosis,12,13 neurodegenerative diseases,5,6,14–16 and 
osteoporosis-like fractures.17 It is not surprising, then, that similar effects are seen in  
                                                
* This chapter is an adaptation of both published2 work and a manuscript accepted for 
publication.1 
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patients with homocystinuria, a genetic condition resulting from deactivating CBS 
mutations. Characteristics of homocystinuria include an increased risk of vascular 
disease, mental retardation, lens dislocation, and skeletal abnormalities.18,19  In addition 
to these homocysteine-related disorders, CBS has also been implicated in a number of 
other diseases ranging from Alzheimer’s Disease6 and Down’s Syndrome14 to 
hypertension8 and preeclampsia.20 
Despite the importance of CBS activity in cellular signaling and human health, 
remarkably few chemical probes are available with which to study its activity. Currently, 
there are only two widely recognized CBS inhibitors, aminooxyacetic acid (AOAA) and 
hydroxylamine (HA) (Figure 3.1).21,22 Both have the ability to inhibit relevant CBS 
activity in the range of 1–10 mM;23,24 however, both also target pyridoxial 5’-phosphate 
(PLP), the cofactor and reaction site of all three previously studied enzymes, namely 
CBS, CGL, and TS.21,22 These compounds, therefore, are not selective for CBS over other 
PLP-dependent enzymes.25 Additionally, only one biological activator of wild type 
human CBS is known, S-adenosyl-L-methionine, (AdoMet).4,26 Not only could new 
activators potentially aid those suffering from homocystinuria and aid in the investigation 
of in vivo CBS activity, but such activators could help decipher the mechanism of CBS 

















In an attempt to address these issues, we have used both AzMC and AzCC in  
screening efforts to identify novel CBS inhibitors and activators. We first used AzMC in 
the screen of a library of known bioactive and clinically used compounds against the 
highly active, truncated form of CBS, CBS !1-413, with the specific goal of discovering 
potent and selective inhibitors. We then applied AzCC in a smaller screen against the 
wild type human CBS, searching for both activators and inhibitors of CBS activity.  
 
3.2 Materials and Methods  
3.2.1 General considerations. All chemicals were purchased from commercial 
sources and used as received unless indicated otherwise. Fluorescence and UV/Vis data 
were collected using a Molecular Devices Spectra Max M5 plate reader. A subset of the 
Marine Invertebrate Compound Library (MICL-240) containing 240 compounds was 
provided by the Ireland lab via the University of Utah Drug Screening Resource Core 
Facility. The full length, wild type CBS enzyme,27 truncated CBS enzyme (residues 1-
413, CBS !1-413),27 and CGL28 were expressed and purified in the Kraus lab as reported 
previously. Tryptophan synthase was purchased from Sigma Aldrich. AzMC and AzCC 
were synthesized as reported in Chapter 2.29,30 Unless otherwise indicated, enzyme 
activity buffer consists of 200 mM Tris HCl, 0.5 mg/mL BSA, 5 "M PLP, pH 8.0.  
3.2.2 Microsource Spectrum Library screen. All studies were carried out in 185 
"L activity buffer and 15 "L DMSO, which was used to dissolve both the 7-azido-4-
methylcoumarin and the library compounds. The probe concentration was 10 "M, the 
cysteine and homocysteine concentrations were each 2.5 mM, the final concentration of 
each library compound was 50 "M, and 0.25 "g of CBS !1-413 was used in each well. 
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Immediately following the addition of substrates, the fluorescence of the mixture at 450 
nm (!ex = 365 nm) was monitored for 1 h. The plate reader was set up to automatically 
shake the plate for 30 s prior to the first data point and for 5 s between each data point 
(every min). Comparison of the screening results with a DMSO control was used to 
identify compounds that modified CBS activity in this screen. 
3.2.3 Microsource Spectrum Library dose-dependence hit validation. Hit 
validation studies were carried out with 150 "L activity buffer and 50 "L DMSO, which 
was used to dissolve both the 7-azido-4-methylcoumarin and the compound. The probe 
concentration was 10 "M, cysteine and homocysteine concentrations were each 2.5 mM, 
and 0.25 "g CBS #1-413 was used to give a final concentration of 40 nM. The 
compounds were preincubated with the enzyme for 30 min. As before, immediately 
following the addition of AzMC and substrates, the fluorescence of the mixture at 450 
nm (!ex = 365 nm) was monitored for 1 h. The plate reader was set up to automatically 
shake the plate for 30 s prior to the first data point and for 5 s between each data point 
(every min). Relative rates were determined after background subtraction. 
3.2.4 Microsource Spectrum Library hit validation against NaHS. Experiments 
designed to identify hits that react with NaHS rather than CBS were carried out in 180 "L 
activity buffer and 20 "L DMSO, which was used to dissolve both the 7-azido-4-
methylcoumarin and the compound. For each inhibitor, the concentration of NaHS was 
held steady at 100 "M, the probe concentration was 10 "M, and the concentration of 
compound was varied from 0–100 "M. Each plate was incubated for 30 min prior to 
measuring fluorescence. 
3.2.5 Microsource Spectrum Library hit validation against AMC. Experiments 
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designed to identify hits that react with AMC rather than CBS were carried out in 180 !L 
activity buffer and 20 !L DMSO, which was used to dissolve both the 7-azido-4-
methylcoumarin and the compound. The concentration of AMC was fixed at 5 !M, and 
the compound concentration varied from 0–100 !M. The assays were incubated for 30 
min before fluorescence was measured. 
3.2.6 Counterscreen of validated hits using CGL and TS. To determine the 
selectivity of hits, identified inhibitors of CBS were counterscreened against CGL and 
TS. Experiments were either carried out using 150 !L activity buffer with 50 !L DMSO 
used to dissolve AzMC and the inhibitors for TS studies or 180 !L activity buffer with 20 
!L DMSO for CGL. Inhibitor concentration was varied from 0 to 200 !M in the presence 
of 2.5 mM cysteine, 2.5 mM homocysteine, and either 3 !g CGL (375 nM) or 5 !g TS 
(714 nM).   
3.2.7 MICL-240 initial screen.  The MICL-240 library of compounds was 
screened in duplicate using 10 !M AzMC, 0.25 !g WT CBS, 10 mM GSH, 2.5 mM 
Hcys, 2.5 mM Cys, and 2 !g of each compound in 100 !L of solution containing 4% 
DMSO, 200 mM Tris HCl, 0.5 mg/mL BSA, 5 !M PLP, pH 8.0.  
3.2.8 MICL-240 screen initial validation for dose-dependence. Compounds 
capable of reducing wild type CBS activity to less than 50% in the initial MICL library 
screen were further validated at 4 !g compound using 10 !M AzMC, 2.5 mM Hcys, and 
2.5 mM Cys, in 100 !L of solution containing 7% DMSO, 200 mM Tris HCl, 0.5 mg/mL 
BSA, 5 !M PLP, and 10 mM GSH, pH 8.0 both with and without 0.25 !g WT CBS. The 
no-enzyme rate was determined to be “background” and was subtracted for the CBS-
induced rate. Additionally, both DMSO and 50 !M S-adenosylmethionine were used as 
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controls with all data standardized to background-subtracted DMSO controls.  
3.2.9 MICL-240 screen secondary validation for inhibition in the presence of 
AdoMet. Compounds that demonstrated concentration-dependent inhibition of WT CBS 
based on the initial screen and validation were further tested at a set concentration of 200 
!M. Each reaction had 100 !L total volume with 5% DMSO, 200 mM Tris HCl, 0.5 
mg/mL BSA, 5 !M PLP, 10 mM GSH, pH 8.0. In addition, 10 !M AzCC, 2.5 mM Hcys, 
2.5 mM Cys, 50 !M S-adenosylmethionine, and 200 !M compound were combined with 
or without 0.25 !g WT CBS. The no-enzyme rate was determined to be “background” 
and was subtracted for the CBS-induced rate. All data were standardized to background-
subtracted DMSO controls. This experiment was designed to ensure that the compounds 
are capable of inhibiting enzyme activity in the presence of the endogenous CBS 
activator, S-adenosyl methionine (AdoMet).  
3.2.10 MICL-240 IC50 determination. Of the hits identified in the screening efforts 
described above, compounds that were available in both sufficient quantity and a >90% 
purity based on LC-MS were carried forward for dose-response studies. The IC50 values 
of potential inhibitors of wild type CBS were determined using 0.25 !g WT CBS, 10 !M 
AzCC, 2.5 mM Cys, 2.5 mM Hcys, 300 !M s-adenosyl-methionine in 100 !L total 
volume (5% DMSO, 200mM Tris HCl, 0.5 mg/mL BSA, 5 !M PLP, 10 mM GSH, pH 
8.0). As with the previous validations, the no-enzyme rate was determined to be 
“background” and was subtracted to obtain the CBS-induced rate. All data were 
standardized to background-subtracted DMSO controls.  
3.2.11 MICL-240 control experiments for false positives. To ensure that the lead 
compounds are, in fact, inhibitors of CBS activity, a series of control experiments was 
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run. Any spurious reaction of the compounds with the enzyme, the azidocoumarin probe, 
or other components of the enzyme reaction mixture was controlled for by running 
enzyme-free controls and background subtracting. However, this protocol cannot rule out 
the possibility that the compounds react directly with the H2S produced by the enzyme, 
reducing the amount of H2S available to reduce the probe and ultimately reducing the 
fluorescent signal obtained. To investigate this possibility, we looked at the ability of the 
compounds to decrease the development of fluorescence of 10 !M AzCC in the presence 
of 100 !M NaHS (5% DMSO, 200mM Tris HCl, 0.5 mg/mL BSA, 5 !M PLP, 10 mM 
GSH, pH 8.0). Compounds MNP2-B7 and MNP2-A6 interfere slightly with the 
development of fluorescence at concentrations near their IC50 values (~80 !M). However, 
this modest fluorescence decrease is not enough to account for the decrease in signal seen 
in the enzyme assays. Therefore we conclude that the compounds are indeed inhibiting 
enzyme activity.  
 
3.3 Microsource Spectrum Collection Screen 
 We began our investigation into novel inhibitors of CBS "1-413 by screening 
1900 compounds from the Microsource Spectrum Collection. This commercially 
available library contains compounds selected to provide a wide range of biological 
activities and structural diversity including approximately 50% clinically used drugs, 
30% natural products from sources worldwide, and 20% compounds with known 
biological activities. AzMC was used for this initial screen as it was more readily 
synthesized and more thoroughly investigated. As mentioned previously, the truncated 
enzyme was used for this principle screen as it proved a simpler starting point than the 
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less active, AdoMet-responsive full length CBS. The library was screened in duplicate at 
50 !M compound concentration, resulting in the identification of 70 compounds for 
further investigation. These results are depicted schematically in Figure 3.2.   
3.3.1 Initial hits. Once initial inhibition properties were determined for all 
compounds at one concentration (50 !M), the effect of the lead inhibitors on the assay 
directly and on the enzyme at varying inhibitory concentrations was also investigated. In 
total, 12 compounds with significant inhibition at 150 !M (Figure 3.3) were validated. It 
is interesting that benserazide, a known inhibitor of the PLP-dependent enzyme DOPA 
decarboxylase,31–33 came up as a top hit. While DOPA decarboxylase is not known to 
catalyze the production of H2S, the fact that a known inhibitor of PLP-dependent 
enzymes came up as a hit in our screen gives us confidence in our assay.  
3.3.2 Inhibitor validation: false positives. Though the one dozen lead compounds 
were validated in the absence of CBS and possessed concentration-dependent inhibition 
(IC50), it is possible that several of the inhibitors interact with other components of our 
assay rather than directly with the enzyme. For example such “false positive” lead 
compounds could react directly with the hydrogen sulfide being detected, resulting in a 
lower readout despite their lack of interaction with CBS itself. Indeed, several of the top 
inhibitors contain electrophilic moieties that could display direct H2S reactivity. For 
example, piperine contains a classical Michael acceptor34 and does react directly with 
NaHS during further testing. The compounds 1,4-naphthoquinone, 12a-hydroxy-5-
deoxydehydromunduserone and alpha-mangostin also appear to interact directly with 
NaHS (Figure 3.4).  

































































































































































































































































































































Figure 3.3 Lead Compounds from the initial validation of Microsource Spectrum 
Collection screen against 0.25 !g CBS using AzMC. Values represent IC50 unless 
















fluorescence of AMC, resulting in a lower readout than the control while having no direct 
effect on the enzyme. Dinitrophenol and dinitrocatechol seem to quench the fluorescence 
of 5 !M AMC (Figure 3.4) and were therefore deemed “false positives.”  
3.3.3 Inhibitor selectivity. The selectivity of the previously validated CBS 
inhibitors for CBS over the closely related, PLP-dependent enzymes CGL and TS (Table 
3.1) was determined using the same AzMC-based assay because these enzymes are also 
capable of catalyzing the production of H2S from cysteine and homocysteine as described 
in Chapters 1 and 2. While most of the compounds showed similar activity against all 
three enzymes, benserazide and fraxetin were significantly more potent against CGL than 
CBS. Tangeritin, on the other hand, was selective for CBS, displaying slightly less  
 
Figure 3.4 Examples of false positives discovered from the Microsource Spectrum 
library screen. a) 1,4-naphthoquinone in the presence of: 10 !M AzMC (black) 
alone, 10 !M AzMC and 100 !M (red), and corrected for background (blue). 1,4-
naphthoquinone reacts with H2S. b) 2-4-dinitrophenol alone (black), with 5 !M 
AMC (red), and corrected for background (blue). 2-4-dinitrophenol is an example of 






































Table 3.1: Selectivity of lead compounds showing IC50 values in !M 
Compound CBS CGL TS 
1,4-naphthoquinone 35 >>200 4 
"-mangostin 78 N/A 38 
apigenin 83 63 86 
amiloride 89 71 74 
rutin 116 73 90 
fraxetin 134 73 >>200 
tangertin 46 (IC75) >>200 71 (IC75) 




potency towards TS than CBS and no inhibition towards CGL below 200 !M. 
Interestingly, 1,4-naphthoquinone also showed no inhibition of CGL activity. This 
is counterintuitive with the assumption that 1,4-naphthoquinone is a false positive that 
reacts directly with H2S or NaHS. Taken together, our initial screening of a small 
chemical library yielded two compounds, 1,4-naphthoquinone and tangeritin, which 
specifically inhibit CBS over CGL. 
 
3.4 The Marine Invertebrate Compound Library (MICL) Screen 
 Our screening of the Microsource Spectrum Collection against CBS #1-413 
provided a nice starting point for the identification of novel CBS chemical probes and 
validated the azidocoumarin complexes as tools with which to study H2S-producing 
enzymes in a high throughput setting. However, in our goal of discovering new in vivo 
modulators of CBS activity, we were interested in not only inhibitors, but activators as 
well. To this end, we turned our attention to the screen of wild type human CBS. This full 
length enzyme is less active than the truncated form, but contains the regulatory 
(AdoMet-binding) domain. It is therefore possible to screen this enzyme for compounds 
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that significantly increase activity in addition to those that inhibit activity. 
Natural products isolated from marine invertebrates have been an exceptional 
source of chemical diversity and pharmaceutical lead compounds.35–42 With the aim of 
streamlining the initial screening process while maximizing the chemical diversity that 
can be sampled, our collaborators in the Ireland lab created a protocol for fractionating 
marine invertebrate extracts.43,44 They then selected a series of chemically diverse, well-
characterized natural products and synthetic derivatives for use in screening. In the work 
reported in this section, we screened this subset of the “Marine Invertebrate Compound 
Library” consisting of 160 characterized marine natural products and 80 purified 
synthetic derivatives, termed “MICL-240,” for compounds capable of activating or 
inhibiting CBS activity. From this library, we identified eight compounds with IC50 
values below 200 !M (range: 83–187 micromolar) and one activator.  
 3.4.1 Initial results. To begin our investigation, all 240 compounds were screened 
at a set concentration (200 !g / mL) against 0.5 !g wild type CBS using the soluble 
azidocoumarin, AzCC. As shown in Figure 3.5, several initial hits, both activators (green) 
and inhibitors (red), were identified. Compounds capable of reducing the activity of CBS 
by more than 50% were rescreened at 400 !g/ mL to confirm a dose-dependent response 
and validated in the presence and absence of enzyme to correct for any background 
fluorescence. The hits that demonstrated concentration-dependent modulation of enzyme 
activity were subjected to a series of secondary screens.  
3.4.2 Inhibitor validation. In addition to the initial screens described in section 
3.4.1, dose-response curves were measured for lead inhibitors in the presence of the 
endogenous CBS activator, S-adenosyl-L-methionine (AdoMet). We felt that inhibitors 
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in the presence of low levels of AdoMet. These validated hits, with IC50 values, are 
shown in Figure 3.6.  
 In an analogous manner to the Microsource Spectrum Collection screen, we also 
confirmed that our lead compounds were, in fact, directly interfering with the ability of 
CBS to metabolize cysteine and homocysteine rather than interfering with another part of 
the assay. None of the compounds shown in Figure 3.6 demonstrate interference with  
 
Figure 3.5 Heat map of MICL initial screen and further validations. Far left: initial screen 
at 2 !g compound. Middle panel: Inhibitors showing activity reduction greater than 50% 
were checked for concentration dependence using 4 !g compound. Data shown are not 
background corrected for ease of comparison with initial screen. Far right: Second 
validation. Compound inhibition was determined at 200 !M compound in the presence of 
















AzCC, ACC, or H2S.  
3.4.3 Discussion of validated inhibitors. It is interesting that the majority of lead 
inhibitory compounds (2-A6, 2-A9, 2-B7, and 3-C11) from our natural product screen are 
synthetic compounds derived from polyandrocarpamines A and B, 2-aminoimidazolone  
compounds isolated from the ascidian Polyandrocarpa sp.45 The MICL-240 library 
contained 17 compounds from this structural class in plate 2 (wells A2-B8) yet only a 
subset displayed activity in our initial screen and only five displayed activity in both of 
our secondary screens (Figure 3.5).  
An investigation into the structures of the validated leads compared to compounds 
that did not inhibit CBS activity (Figure 3.7) in the initial screen provides some 
information about the structure-activity relationship of these compounds. First, 
compounds containing only the thiohydantoin or aromatic moiety are not good inhibitors  
 



































































of CBS activity (compounds MNP2 A2, A7 and A10). Additionally, compounds MNP2-
A8, MNP2-B6, and MNP2-B8, where both hydroxyl groups are etherified and the 
thiohydantoin either is methylated both at the 3-position and on the sulfur atom or 
replaced by a hydantoin moiety, do not show up as hits. Thiohydantoin methylation alone 
(compound MNP2-B7) does not prevent enzyme inhibition, while replacement of the 
thiohydantion moiety with a hydantoin moiety does (MNP2-B6, MNP2-B3). 
 3.4.4 Potential CBS activator. One of the most exciting results from the MICL 
screen with a broad range of potential implications was the identification of a novel CBS 
activator. A compound in well MNP1-C5 (Figure 3.8) increased wild type CBS activity 
by 329 ±19% in the initial screen. This increase was found to be concentration-dependent 
even after all background signals were removed and is equivalent or slightly greater than 
the activation of CBS by 500 !M AdoMet.46,47 While the compound in MNP1-C5 was 
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toxicities in vitro,37,48,49 LC-MS analysis indicated that the compound had decomposed 
during storage. There was not enough sample available to identify the active component.  
 In an attempt to study structurally related compounds, we obtained a series of 
bengarcarboline derivates from the Pingaew lab.38 Unfortunately, none of the synthetic 
derivatives were capable of activating CBS.  
 
3.5 Conclusion 
  In Chapter 2 we explored the development of two H2S-probes and their use in 
studying the activities of H2S-producing enzymes. In this chapter, we have extrapolated 
these assays to include utility in high throughput screening. From the two screens 
described in this chapter we have identified a number of inhibitors more potent that those 
currently known. If it is in fact inhibiting CBS, 1,4-naphtoquinone would be the most 
potent inhibitor of CBS reported. While not quite as potent, the discovery of such 
compounds as alpha-mangostin, MNP2-A6, and MNP2-B7 is remarkable. These 
inhibitors show a marked improvement over the more traditional CBS inhibitors, AOAA 









Figure 3.8 Structure of bengacarboline, a potential activator of full length CBS 
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the door to CBS-targeting experiments. In addition to the identification of novel CBS 
inhibitors, we also discovered a possible CBS activator. Though we were unsuccessful in 
identifying the structure of this compound, it gives us hope that small molecules other 
than AdoMet may be capable of enhancing CBS activity.  
 The aim of future work on this project will be to improve the potency and 
selectivity of CBS inhibitors and to identify activators of CBS activity. Larger, more 
diverse screens should aid in this endeavor. Ideal inhibitors will have an IC50 < 10 !M 
against CBS with a potency against CGL at least 10-fold higher. Acceptable activators 
will double CBS activity at 10 !M. Because the Pingaew library contained p-
nitrobenzenesulfonyl derivatives of bengcarboline, it may be useful to screen a library of 
smaller tryptamines with similar structures to bengcarboline. It is possible that this added 
moiety prevented the screened compounds from binding and activating CBS. 
Additionally, serine or cysteine derivatives with a fluorinated "-carbon may also serve as 
potential CBS inhibitors, though most likely not selective inhibitors. These amino acid 
derivates would not be capable of a proton abstraction and would therefore trap the 
external aldimine. However, it may be more practical to synthesize derivatives of the 2-
aminoimidazolone compounds based on our SAR findings.  
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As described in pervious chapters, hydrogen sulfide (H2S) appears to be a 
salubrious gas at low micromolar concentrations, serving as a signaling molecule in 
numerous human organs, specifically the brain1–6, cardiovascular system7–12, and 
gastrointestinal tract.13–15 Given their importance to human health, it is not surprising that 
reactive sulfur species such as H2S and the transsulfuration pathway have become 
potential targets for new therapeutics. One can imagine two drug classes that might 
attenuate H2S levels in vivo: those that moderate the activity of H2S-producing enzymes 
and those that release H2S either directly or indirectly. The first type of potential 
therapeutic was discussed in Chapter 3. These compounds can activate or, more often, 
inhibit CBS and CGL activity. While such compounds were designed primarily for use as 
chemical probes for endogenous reactive sulfur species such as H2S, it is not 
unreasonable to propose that potent, selective inhibitors might one day see use as 
therapeutics for CBS-upregulated diseases. The second class of potential H2S-targeted 
therapeutics, those that directly increase cellular concentrations of reactive sulfur species, 
will be discussed and investigated in this chapter.  
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4.1.1 Hydrogen sulfide-releasing agents. Sulfide salts, such as NaSH, Na2S, and 
CaS, can release hydrogen sulfide and are frequently used as sources of H2S in biological 
studies. While these compounds are simple, readily available, and soluble in aqueous 
solutions, they are not ideal for use as therapeutics. Sulfide salts produce a quick and 
often intense burst of sulfide rather than the slow, controlled released desired in a 
therapeutic.16,17 Additionally, some studies report no change in plasma H2S levels upon 
injection of NaHS,10 possibly due to the immediate oxidation of sulfide into reduction 
labile pools.1 Ideally, a potential drug would have a consistent H2S-release rate with a 
small concentration of H2S given off over a long time period. To accomplish this, 
attention has turned to hydrogen sulfide-donating compounds, that is, synthetic or 
naturally occurring complexes that raise sulfide levels through some reaction or 
metabolic pathway within the cell.18 There are two types of such donating compounds: 
those that occur naturally, often in the food we eat, and those that are designed and 
synthesized by chemists.  
4.1.2 Naturally occurring hydrogen sulfide-donating compounds. Many of the 
foods we eat, such as garlic, wasabi, horseradish, and broccoli, may contain compounds 
that produce H2S when metabolized. The consumption of garlic, for example, has long 
been known to be beneficial to human health, especially in the H2S-sensitive 
cardiovascular and anti-inflammatory systems. In fact, these physiological effects may be 
the result of organosulfur-rich garlic being metabolized to produce H2S. Garlic contains 
diallyl thiosulfinate, which is broken down to form the polysulfides diallyl disulfide 
(DADS) and diallyl trisulfide (DATS) (Figure 4.1).11,17,19,20 It has been shown that these 









Further validating this idea is the finding that injection of DADS into mice increases the 
concentration of exhaled H2S.21 More recently, DATS has been used in a clinical trial of 
5000 patients, giving promising results. The trial found that those taking a DATS 
supplement (200 mg/day) had 22% less instance of cancer over a 5-year period and a 
47% less instance of gastric cancer.19,22 This result could be due to reduction-induced 
hydrogen sulfide release as initially reported or through some other reactive sulfide 
intermediate such as persulfides.23 In either case, this result underscores the importance 
of reactive sulfide complexes to human health and the importance of developing new 
H2S-donating therapeutics.  
4.1.3 Synthetic hydrogen sulfide-donating compounds. In addition to naturally 
occurring species, new H2S-donating agents have also been designed and synthesized. 
One of the first complexes developed was GYY4137 (Figure 4.1), a derivative of 
Lawson’s reagent. While GYY4137 does produce the desired slow release of H2S, it is 
not overly efficient, giving off under 10% H2S in 90 minutes at pH 3.0 and less than 1% 
at physiological pH.  
One of the most promising H2S-donating compounds to date is anethole 
 


















dithiolethione (ADT). ADT contains an aromatic H2S-producing motif that is readily 
bound to other drugs through an ether linkage. The ADT-derivative of many therapeutics 
have been synthesized and tested including, L-DOPA, sildenafil, and numerous NSAID 
pain relievers.17 The negative effects of NSAIDs on the gastrointestinal tract were 
mitigated by the addition of this H2S-donating moiety,13 most likely because H2S aids in 
mucosal defense and repair.  
Given the therapeutic potential, we set out to discover new H2S-donating agents. 
These compounds should be trigged by some biological process or condition to produce 
H2S under cellular conditions rather than in buffer alone. Additionally, these complexes 
need to be nontoxic. Such compounds should prove useful in studying the effects of H2S 
and may have therapeutic potential in the treatment of a number of H2S-related disorders.  
 
4.2 Materials and Methods 
4.2.1 General considerations. All chemicals were purchased from commercial 
sources and used as received unless indicated otherwise. The 1H NMR data were 
collected on a Varian 400 MHz NMR spectrometer. Chemical shifts are reported in parts 
per million referenced to internal standard (CH3)4Si = 0.00 ppm. Fluorescence and 
UV/Vis data were collected using a Molecular Devices Spectra Max M5 plate reader.  
4.2.2 Initial screen of thiuram disulfide library using AzMC. A library of thiuram 
disulfide was screened at 100 !M in 95% activity buffer (50 mM BisTris, 100 mM NaCl, 
pH 6.5) and 5% DMSO using 10 !M AzMC. Reactions took place in buffer alone, or 
with a reducing agent present (10 mM glutathione, 250 !M cysteine, or both). After 1 h 
incubation at room temperature, the fluorescence was measured according to the AzMC 
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procedure established in Chapter 2.  
4.2.3 Methylene blue assay. The methylene blue assay was conducted as indicated 
in Chapter 5. Reaction mixtures were prepared in a 500 !L well plate in triplicate. A 3 
!L aliquot of thiuram disulfide (10 mM stock) in DMSO was diluted in 297 !L buffer 
(50 mM BisTris, 100 mM NaCl, 0.01% Brij 35, pH 6.5) either with or without 2 mM 
glutathione. The plate was sealed with foil tape and left at room temperature for 24 h. For 
the methylene blue assay, a 70 !L aliquot from each well was reacted with 60 !L 10% 
w/v trichloroacetic acid, 30 !L 1% w/v zinc acetate (aq), and 20 !L 30 mM ferric 
chloride (in 1.2 M HCl). Addition of 20 !L 20 mM N,N-dimethyl-p-phenylenediamine 
sulfate (in 7.2 M HCl) yielded a blue color, which was detected after 10 min at 670 nm.  
4.2.4 Reducing agent dependence. The reactivity of 4C (100 !M) was studied in 
presence of 2 mM reductant (glutathione, cysteine, BME, DTT, and TCEP) and alone 
(control). A background control was run for each, substituting DMSO for 4C. The data 
discussed are background corrected for the DMSO control. Each reaction, performed in 
triplicate, contained 99 !L buffer (50 mM BisTris, 100 mM NaCl, 0.01% Brij 35, pH 6.5) 
and 1 !L DMSO and was incubated for 1 h prior to testing. As described in section 5.2.3, 
a 70 !L aliquot of each was used in the methylene blue assay.  
4.2.5 pH dependent production of H2S from 4C. Using the same stock solution, 
six pH buffers were made (6.5–9.0) containing 50 mM Bis Tris Propane, 100 mM NaCl, 
and 0.01% Brij 35. In 100 !L final volume were placed 1 !L DMSO (used to dissolve 
4C, 100 !M) and 2 mM cysteine. (The remaining volume was made up from buffer.) As 
in section 4.2.4, a DMSO control was used to calculate background. After 1 h reaction 
time, each reaction was tested using the methylene blue assay. 
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4.2.6 Sulfolane controls.The reactivity of 4C (100 !M) was compared to that of 
DMSO and sulfolane (100 !M) in the presence and absence of 2 mM cysteine. The 
reactions took place in 99 !L buffer (50 mM Tris HCl, 100 mM NaCl, 0.1% Brij 35, pH 
8.0) and 1 !L DMSO and was incubated 1 h prior to testing with methylene blue. An 
absorbance reading was taken 10 min after mixing of methylene blue assay. 
4.2.7 Comparison of H2S-donating compounds with reducing agents. GYY4137, 
4C, DADS, and DMSO (control) (100 !M) were reacted with 5 mM reducing agent 
(TCEP, glutathione, cysteine, BME, DTT, and buffer [control]) in 1 !L DMSO and 97 
!M buffer (50 mM Tris HCl, 100 mM NaCl, 0.01% Brij 35, pH 8.0). After 2 h reaction, 
the methylene blue assay was used to determine H2S concentration.  
4.2.8 Kinetic comparison of H2S-donating compounds. In 193 !L buffer (50 mM 
Tris HCl, 100 mM NaCl, 0.01% Brij 35, pH 8.0) and 7 !L DMSO were dissolved 100 
!M 4C, DADS, or GYY4137, 2 mM cysteine (or buffer for controls), and 10 !M AzMC. 
The fluorescence of the plate was read at 450 nm (exciting at 365 nm) immediately 
following the addition of the H2S-donating compounds.  
4.2.9 Purification of 4C. An 11.73 mg sample of 4C was dissolved in DMSO and 
CHCl3 and dried onto silica before the solvent was removed. A silica column was run, 
eluting with 2% MeOH in CHCl3. Two products were collected, each a yellow oil. The 
masses of each was determined using GC-MS, and the activity of each in the presence of 
glutathione was determined. 
4.2.10 Synthesis of dimethyltin compounds, 3 and 4. Compounds 3 and 4 were 
synthesized according to previously published methods (Figure 4.2)24,25 Briefly, 







solution in ethanol (14 mL) was added and allowed to stir for 30 min. An aqueous 
solution of dimethyltin chloride (0.56 g, 1.5 equiv) was added and allowed to stir for 3 h. 
The solvent was removed before the resulting solid was dissolved in CH2Cl2 (40 mL) and 
washed with water (2 x 20 mL) and brine (1 x 13 mL). The organic layer was collected, 
dried over anhydrous MgSO4, filtered, and the solvent removed yielding 3 as a while 
solid in 33% yield. 1H NMR (!, CDCl3) 1.008 (s, 6H), 6.885 (m, 2H), 7.446 (m, 2H).  
Compound 4 was synthesized in an analogous way, giving a 35% yield of a 
yellow solid. 1H NMR (!, CDCl3) 0.99 (s, 6H), 2.22 (s, 3H), 6.71 (d, 1 H), 7.28 (s, 1H), 
7.33 (d, 1H).  
 4.2.11 Synthesis of benzopentathiepins 5 and 6. The pentathiepin ring was 
synthesized as described previously.25,26 A solution of 3 (0.1 g, 1.0 equiv) in anhydrous 
CH2Cl2 (10 mL) was cooled in ice. Sulfur monochloride was added (50 "L, 1.5 equiv) 
and the reaction stirred for 4 days (monitored by TLC), warming to room temperature. A 
0.5 N solution of HCl (10 mL) was added to quench the reaction. The organics were 
extracted with 3 x 10 mL CH2Cl2, washed with 1 x 10 mL brine, dried over anhydrous 
Na2SO4, and filtered, and the solvent was removed. The crude product was further 
purified on a silica column, eluting with hexanes to give 5 as a yellow oil in 27% yield. 

















0˚C- RT, 4 d
5, R=H
6, R=  Me
 
Figure 4.2 Synthetic scheme for synthesis of benzopentathiepins 5 and 6.  
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yielded 6 as a yellow oil in 38% yield. 1H NMR (!, CDCl3) 2.37 (s, 3H), 7.14 (d, 1H), 
7.65 (s, 1H), 7.69 (d, 1H). LC-MS experiments gave no useful data.  
4.2.12 Preliminary studies of H2S-release from 3-methylbenzopentathiepin, 6. A 
solution of 3-methylbenzopentathiepin (6, 34.17 mg) in CH2Cl2 (1.36 mL) was 
previously prepared for mass spectrometry studies. Because of evaporation, the exact 
concentration of 6 used in this study may not be accurate. A 10 "L aliquot of 6 was 
diluted further with 90 "L DMSO to form a 10 mM solution. This dilution was used in 
200 "L total volume with 2 "L 6 solution (100 "M), 10 "M DMSO used to dissolve 
AzMC (10 "M), and 5 mM glutathione in buffer (200 mM Tris HCl, 100 mM NaCl, pH 
8.0).  
 
4.3 Thiuram Disulfides as Potential Hydrogen Sulfide-Releasing  
Agents 
 We hypothesized that thiuram disulfides might serve as potential H2S-donating 
agents. Two such compounds are known drugs, disulfiram and imuthiol. These 
compounds should, therefore, not be overly toxic as they have been well studied in 
humans. During an initial screen of a thiuram disulfide library  (Figure 4.3), we found 
that several compounds produced H2S in the presence of 10 mM glutathione or 250 "M 
cysteine (Figure 4.4a). Upon countertesting these results using the methylene blue assay 
and 2 mM glutathione, we confirmed the release of H2S (Figure 4.4b). While several 
other thiruam disulfides produce small amounts of H2S (up to 0.5 equiv), 4C was by far 
the greatest producer of H2S. (A note should be made that often less H2S was seen after 
































































































































































































































































































































































































































































due to evolution of H2S into the headspace of the eppendorf tube. Indeed, a higher 
concentration of H2S is recorded during experiments with either greater volume or a 
smaller headspace.) We therefore, will focus on compound 4C for the remainder of this 
section.  
 4.3.1 Compound 4C reactivity. Upon discovery that compound 4C produces H2S 
in the presence of a glutathione, we had two questions: first, what is required for this 
reaction to take place? And second, why does 4C produce so much more H2S than related 
compounds? To answer the first question, a number of reducing agents were tested 
(Figure 4.5). We found that H2S release from 4C was dependent on reduction of 4C by a 
thiol-based reductant. While glutathione, DTT, BME, and cysteine all induced H2S-
release from 4C, the use of TCEP as the reductant resulted in very little H2S release.  
 To answer the second question, we compared sulfolane and 4C (Figure 4.6) in 
the presence and absence of 2 mM glutathione. Unlike 4C, sulfolane does not produce a 





































Figure 4.5 Reactivity of 4C (100 !M) with reducing agents (2 mM) after 30 min 












also investigated the pH dependence of this reaction. We ound that H2S-release was not 
severely pH dependent (Figure 4.7), but that a slight peak exists at pH 8.0. Lastly, we 
attempted to quantify the amount of H2S produced using both the AzMC and methylene 
blue assays (Figure 4.8). We found that roughly two equivalents of H2S were produced 
independent of which assay was used.  
 4.3.2 Comparison of 4C with other H2S-donating compounds. Having established 
4C as a novel H2S-donating compound, we set out to validate it against two other H2S-
donating compounds reported in the literature, DADS and GYY4137. We first compared 
the response of the three compounds against various reducing agents (Figure 4.9). The 
first observation of note is that 4C appears to release the most H2S over the 2 h time 
period (GYY4137 is close in the presence of TCEP, although this reaction is not 
physiologically relevant). As expected, 4C requires a thiol-based reductant as does, it 
appears, DADS. In fact, the addition of TCEP to either 4C or DADS does not stimulate  





















Figure 4.6 Sulfolane (100 !M) control versus 4C (100 !M) in the presence (red) and 













































































Figure 4.8 Comparison of methylene blue (blue) and AzMC (black) assays. It 
appears that roughly two equiv of H2S are produced from 4C independent of assay 























Figure 4.7 pH dependence of H2S production from 4C (100 !M) in the presence 
(red) and absence (black) of cysteine (2 mM) after 30 min incubation. The 













reported to react with glutathione and other thiols in red blood cells,10,17 GYY4137 has 
the opposite trend as 4C and DADS in our hands. Under our conditions, GYY4137 does 
not produce any H2S upon the addition of glutathione under our conditions and produces 
very little H2S in the presence of the other thiol-containing reducing agents. GYY4137 
does react quite strongly, however, with the nonthiol reducing agent, TCEP.  
  Because the rate of H2S production will be important in biological applications, 
we also compared the kinetics of H2S release from DADS, GYY4137, and 4C (Figure 
4.10). In reports, GYY4137 released 4% of all possible H2S over the first 10 min and 
another 4% per hour after that for the remaining 80 min at pH 3.0. This same pattern is 
not seen in our studies at pH 8.0. Instead, we see a quick release of H2S before the plate is 
read ( < 30 s) with no subsequent release over the following 2 h. DADS follows a similar 
pattern. However, H2S-release from 4C is gradual over the first 40 min before tapering 
off.  
4.3.3 Compound 4C structure determination. We were excited to identify a potent  
 
Figure 4.9 Production of H2S from known H2S-donating compounds (100 !M) in the 



































new H2S-donating compound. Hoping that it would also explain the structure-activity 
relationship of our initial screening results, we set out to determine the mechanism by 
which H2S is released from 4C. While the 1H NMR spectrum was consistent with the 
proposed structure of 4C (Figure 4.11), mass spectral analysis of 4C alone indicated the 
absence of the expected mass (419.94). Instead, only two unidentified masses were seen: 
312.00 and 334.98. We theorized that rather than the thiuram disulfide, 4C could, instead, 
be a thiourea. In fact, a thiourea library was later screened, but yielded no H2S-donating 
leads (Figure 4.12).  
After extensive trial and error, 4C was purified on a silica column, yielding two 
pure compounds, one with the observed masses of 312.00 and 334.98, which we 
hypothesize to be the thiourea (Figure 4.11), and another with the lower mass of 279.09. 
Upon testing of each of these pure compounds, neither produced H2S in the presence of 
glutathione. 
It came to our attention that inorganic sulfur (S8) could be the H2S-releasing 
 
Figure 4.10 Kinetic response of 100  !M 4C (red), DADS (blue), GYY4137 (green), 
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aqueous or organic solvents, examination of the liquor when suspended in DMSO gave 
the same results as 4C. In fact, addition of 100 mM BME to the liquor gave a 25 mM 
NaHS-equivalent solution that was later used in experiments with crude oil (Chapter 5).   
 
4.4 Benzothiepins as Hydrogen Sulfide-Releasing Agents  
 Based on our experience with inorganic sulfur, knowledge of DADS, and recent 
reports indicating the biological importance and relevance of polysulfides and 
persulfides,23,28 we hypothesized that an organic polysulfide might have utility as a 
reduction-labile, H2S-donating therapeutic. Our collaborators in the Ireland lab identified 
 
Figure 4.12 Various thiourea derivatives (100 !M) are unable to produce 
H2S in the presence of reducing agents, while 4C does form H2S in both 











































such a compound in 1991, varacin (Figure 4.13).29 Varacin is a unique benzopentathiepin 
with antitumor properties.24,30,31 While the synthesis of varacin has since been 
established,29,31 it is not overly straightforward nor high-yielding. We therefore opted to 
begin out studies with a simpler benzopentathiepin system (Figure 4.13).   
 4.4.1 Synthesis of benzopentathiepins. The synthesis of both benzopentathiepin 
(5) and 3-methylbenzopentathiepin (6) are described pictorially in Figure 4.2. There are 
two major protocols for establishing the pentathiepin ring. The most common procedure 
involves the use of S8 in neat ammonia. For reasons described above, we chose to avoid 
the risk of an S8 contaminant and chose instead to go through a dimethyltin intermediate. 
We first activated the dithiol starting material using dimethyltin chloride. The 
pentathiepin ring was then inserted using sulfur monochloride (S2Cl2). Extraction into 
organic solvent gave the product in 90% purity; however, because pure compounds were 
essential to our experiments, a silica column was used to further purify each compound. 
4.4.2 Preliminary studies of 3-methylbenzopentathiepin. Before further validating 
the structure of compounds 5 and 6, we were interested to know if they were capable of 































Therefore a stock solution was made using CH2Cl2 and further diluted in DMSO before 
experiments were conducted. Compound 6 alone does not release hydrogen sulfide in 
buffer; however, upon addition of 5 mM glutathione, the evolution of H2S can be seen 
over the first 30 min (Figure 4.14). This supports our hypothesis that these pentathiepins, 
like other polysulfides, may be useful H2S-donating compounds. 
4.4.3 Future work. Validation of 5 and 6 remains to be done. Along with a more 
detailed NMR study, mass spectroscopy and elemental analyses will be used to confirm 
the addition of three sulfur atoms to the parent dithiols (the addition of one sulfur atom to 
make a five-membered ring or five sulfur atoms to make a nine-membered ring could 
also be expected). Additionally, solubility in aqueous solution is desirable. Therefore, a 































Figure 4.14 Preliminary studies of 6 (~100 !M) in the presence (red) and absence 




 Because of the important functions of hydrogen sulfide and other reactive sulfur 
species in biology, H2S-donating compounds may have great value. These agents could 
be used to further investigate the production of H2S in vivo. They could also potentially 
have use as therapeutics in the treatment of numerous H2S-associated diseases.17,32 To 
this end, we have investigated a new H2S-donating compound, 4C. Though the exact 
H2S-releasing contaminant in 4C remains a mystery, the conditions required to produce 
H2S from 4C have been thoroughly investigated using both fluorescent and colorimetric 
assays. It has been established that this contaminating compound is reduction-labile (such 
as a persulfide, polysulfide, or inorganic sulfur) and produces a controlled release of H2S 
over 40 min in the presence of a reducing thiol. 
Two polysulfides based on the natural product varacin have been designed and 
synthesized. Preliminary evidence suggests that these benzopentathiepin compounds 
release H2S over a 20-min interval upon exposure with thiol-based reducing agents. 
These compounds show potential as novel H2S-donating compounds and will hopefully 
lead to more benzopentathiepin-based agents with improved solubility.  
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LANTHANIDE COMPLEXES AND COLORIMETRIC DYES  
AS PROBES FOR HYDROGEN SULFIDE WITH  




Hydrogen sulfide (H2S) is a gas notorious for its noxious smell and toxicity. As 
emphasized in pervious chapters, H2S plays key roles in cellular signaling pathways and 
may be critical for maintaining vascular and neurological health.1 However, hydrogen 
sulfide is also ubiquitous in the environment. This gaseous molecule is a key contaminant 
in crude oil2 and ground water3 and is an important cause of work-related sudden death.4 
Due to the industrial, environmental and biological importance of H2S and related 
sulfides, there has been significant interest in the development of chemical approaches 
for monitoring its presence.  
Described in greater detail in Chapter 1, traditional approaches to hydrogen 
sulfide detection include the methylene blue assay first reported by Emil Fischer in the 
late 1800s,5 qualitative analysis of sulfide by precipitation with lead acetate, the use of a  
                                                
* This work is an adaptation of a paper previously prepared for publication.  
Thorson, M. K.; Ung, P.; Tuck, K. L.; Graham, B.; Barrios, A. M. manuscript in 
preparation.  
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sulfide ion selective electrode, and gas chromatography.6 Due to the recent interest in the 
biological roles of H2S, a number of fluorogenic probes for H2S have also been 
developed.7–9 These probes generally rely on sulfide-specific chemistries; most notably 
the sulfide-selective reduction of an aryl azide or nitro group to form an aryl amine with 
concomitant increase in a fluorescent signal.10,11 While these reaction-based probes offer 
significant advantages over other approaches to monitoring H2S, including a sensitive 
fluorogenic signal and a direct and facile assay for the presence of H2S, they have not 
been widely applied to industrially or environmentally relevant samples. In addition, the 
excitation and/or emission profiles often overlap with small molecule absorbance and 
fluorescence and tissue autofluorescence.12,13 One way to get around this difficulty is to 
utilize fluorogenic probes with long luminescent lifetimes14 that allow for time-gated 
fluorescence studies. By allowing the background (organic) fluorescence to decay before 
a signal is read, the signal-to-noise ratio is improved greatly. This enables these probes to 
have utility in scenarios where other fluorescent probes may fail to produce a reliable 
signal.   
 
5.2 Materials and Methods 
 5.2.1 General considerations. All chemicals were purchased from commercial 
sources and used as received unless indicated otherwise. The 1H NMR data were 
collected on a Varian 400 MHz NMR spectrometer. Chemical shifts are reported in parts 
per million referenced to internal standard (CH3)4Si = 0.00 ppm. Fluorescence and 
UV/Vis data were collected using a Molecular Devices Spectra Max M5 plate reader. 
Lanthanide probes were supplied by the laboratory of Dr. Bim Graham at Monash 
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Institute of Pharmaceutical Sciences.  
5.2.2 Screening of lanthanide-based probes. Eight lanthanide probes containing 
an azide functional group were screening for reactivity with hydrogen sulfide. Probe 
fluorescence was determined both with and without 100!M NaHS in buffer (200 mM 
Tris HCl, pH 8). Time-resolved fluorescence was performed using a 500 !s delay and 
integrating over 1000 !s. Probes were excited at both 270 and 360 nm. All probes were 
soluble in buffer with the exception of probe 3, which was dissolved in DMSO.  
5.2.3 NaHS dependence of compounds 1, 2, and 3. A final concentration of 10 !M 
of each compound was used in buffer (200 mM Tris HCl, pH 8.0) and 5% DMSO. 
Optimal excitation of each probe was determined by observing the emission fluorescence 
at 545 nm or 615 nm while varying the excitation wavelength both in the absence and 
presence of 250 !M NaHS (delay: 500 !s, integration: 1000 !s). 
5.2.4 Measuring hydrogen sulfide levels in sour and stripped water. Known 
concentrations of NaHS (0–300 !M) were created and used to make standard curves for 
all three assays. The sour water was diluted sequentially to create a dilution within the 
workable range of all assays. For the compound 3 and AzMC, 10 !M of probe in buffer 
and 5% DMSO was incubated with known NaHS solution for 30 min prior to detection. 
Standard methylene blue protocol was used for validation.15–17 Briefly, a 70 !L aliquot of  
known NaHS concentration was reacted with 60 !L 10% w/v trichloroacetic acid, 30 !L 
1% w/v zinc acetate (aq), and 20 !L 30 mM ferric chloride (in 1.2 M HCl). Addition of 
20 !L 20mM N,N-dimethyl-p-phenylenediamine sulfate (in 7.2 M HCl) yielded a blue 
color, which was detected after 30 min at 670 nm.  
5.2.5 Initial studies with compound 1 in crude oil #4. The 200 !L total solution 
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was composed of 10 !L buffer, 10 !L 0.2 mM probe in DMSO (10 !M final 
concentration), and either 10 !L “control” or “sulfide.” Because of limited NaHS 
solubility in buffer, an alternative form of hydrogen sulfide was used for these initial 
experiments. The liquor of inorganic sulfur pieces suspended in DMSO was combined 
with "–mercaptoethanol (BME) (7 !L BME in 1 mL total solution) to produce “sulfide.” 
To control for the DMSO and BME, a “control” was added to nonsulfide containing 
wells. The “control” solution was identical to the “sulfide,” but contained pure DMSO. 
The “sulfide” solution was later determined to have a concentration equal to that of 25 ±3 
mM NaHS using the AzMC assay in buffer. The solutions were incubated for 30 min 
prior to fluorescence determination. Maximal emission (615 nm) was seen at an 
excitation of 360 nm after a 500 !s delay and 1000 !s integration.  
5.2.6 Initial studies with compound 3 in crude oil #4. The 200 !L total solution 
was composed of 10 !L buffer, 50 !L 0.2 mM probe in DMSO (10 !M final 
concentration) and either 50 !L “control” or “sulfide.” See 5.2.5 for solution definitions. 
Compound 3 gives a maximal emission at 545 nm when excited at 280 nm during time-
resolve fluorescence studies.  
5.2.7 NaHS dependence of compounds 1 and 3 in crude oil #4. The response of 
compound 1 in crude oil was determined in an analogous manner to that described in 
section 5.2.6. A 10 !L aliquot of probe (10 !M final concentration) in DMSO was added 
to 10 !L crude oil and 10 !L buffer in dioxane. The same experiment was conducted 
without oil as a control. Compound 1 was excited at 360 nm and the emission was read at 
615 nm following a 500 !s delay and 1000 !s integration. Compound 3 was excited at 
280 nm to give a signal at 545 nm.  
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5.2.8 Synthesis of 4-azidoazobenzene, 4. 4-azidoazobenzene was synthesized in an 
analogous fashion to our previous azide-based probes. Aniline yellow (1.2 g, 1.0 equiv) 
was suspended in water (25 mL) and allowed to stir at 0 °C in an ice/water bath. 
Concentrated sulfuric acid (6 mL) was added to the reaction in a dropwise fashion to 
maintain the temperature. Sodium nitrate (0.55 g, 1.3 equiv) was dissolved in water (7 
mL), cooled to 0 °C, and added in a dropwise fashion to the reaction over 10 min. The 
reaction was then allowed to stir at 0 °C for 1 h. Meanwhile, sodium azide (0.67 g, 1.6 
equiv) was dissolved in water (5 mL) and cooled to 0 °C. After 1 h, the sodium azide 
solution was added to the reaction mixture in a dropwise fashion, and the formation of a 
red-orange precipitate was immediately observed. The reaction mixture was then allowed 
to warm to room temperature overnight with stirring, and the solid was collected using 
vacuum filtration and washed with water (150 mL). The resulting solid was then 
dissolved in chloroform (200 mL) and ethyl acetate (100 mL), dried over anhydrous 
magnesium sulfate, and filtered, and the solvent was removed to yield a dark powder. 
The powder was dissolved in ethyl acetate (40 mL) and washed with 3 x 20 mL 0.5 N 
HCl, and the organic layer was further washed with 2 x 20 mL of a brine solution. The 
organic layers were collected, dried over anhydrous sodium sulfate, and concentrated. 
The concentrated solution was purified on a silica column, eluding with 1:5 ethyl acetate: 
hexane before being further purified on a silica column eluding with hexanes. The 
resulting solid was the pure 4-azidoazobenzene (0.917 g) in 65.5% yield. 1H NMR (!, 
(CD3)2SO) 7.34 (d, 2H), 7.58 (m, 3H), 7.87 (d, 2H), 7.94 (d, 2H). 
5.2.9 Reactivity of 4-azidoazobenzene. A 100 "L aliquot of 4-azidobenzene was 
reacted with NaHS (0–20 mM) in 200 "L total volume buffer with 5% DMSO used to 
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dissolve the probe. No response was seen between 7-aminoazobenzene and NaHS.  
 
5.3 Results and Discussion of Lanthanide-Based Hydrogen Sulfide  
Probes 
5.3.1 Lanthanide-based probes and their reactivity. After obtaining a small series 
of lanthanide-based aryl azides from the Graham lab, each was studied for reactivity with 
NaHS. During the course of our work, compound 1 was reported in the literature as a 
H2S-selective probe,18 showing a linear response to H2S in the concentration range 
between 80 nM and 1 !M.18 Of the eight compounds tested, three displayed a response 
upon the addition of 250 !M NaHS (Figure 5.1).  
The emission profiles of each compound in the absence and presence of 250 !M 
NaHS are displayed in Figure 5.2. Compounds 1 and 3, upon excitation at 280 nm and 
350 nm, respectively, display increased fluorescence in the presence of NaHS. These 
compounds, especially compound 3, with an approximately 5-fold fluorescence increase, 
should be good “turn-on” fluorescent probes for H2S. Upon excitation at 280 nm, 
compound 2 displays decreased fluorescence in the presence of H2S and can be 
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are significantly red-shifted as compared to that of compound 3, with significant 
absorbance above 300 nm. In contrast, compound 3 has little absorbance above 300 nm 
(Figure 5.3).  
While compounds 1 and 3 both have the potential to serve as H2S sensors with 
significant time-delayed luminescence, the sensitivity of the compound along with their 
excitation profiles will likely influence their utility as probes. As shown in Figure 5.4, 
compound 3 could reliably detect NaHS in concentrations as low as 250 nM in aqueous 
solutions with a linear working range from 250 nM to 300 !M NaHS. Because of its 
sensitivity, large working range, and UV excitation, this compound was predicted to have 
good utility in measuring H2S levels in industrial water samples with little background 
absorbance.  
5.3.2. Hydrogen sulfide detection in sour and stripped water. Large amounts of 
water are used in the process of refining crude oil, and the industry generates significant 
volumes of wastewater.19 This wastewater (often called “sour water” because of its 
characteristic smell) contains large amounts of sulfide, ammonia, and other petroleum  
 
Figure 5.2 Response of compounds 1 (a), 2 (b), and 3 (c) with 250 !M NaHS. Closed 
circles (red) indicate the presence of NaHS while open squares (black) represent 
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Figure 5.3 Excitation sweep of 10 !M compound 1 (blue), 2 (red), and 3 (black) in the 



















byproducts. Before the water can be released into the environment or recycled in the 
refinery, it must be “stripped” of the toxic and corrosive byproducts. Specifically, the 
Environmental Protection Agency stipulates that the hydrogen sulfide in water released 
into the environment must be below the olefactory detection limit (estimated at approx. 
15 !M).14 To validate the utility of compound 3 for detecting hydrogen sulfide in 
aqueous samples, we obtained samples of “sour” and “stripped” water from a local oil 
refinery. Using the standard curve shown in Figure 5.4, we measured the concentration of 
H2S in our industrial water samples (Figure 5.5). The sour water sample had a very high 
sulfide concentration of 40 ±4 mM as measured by probe 3. This measurement was 
independently verified using two proven quantitative tests for H2S, the methylene blue 
test and the fluorescent probe AzMC.5,20 The stripped water sample had a significantly 












































our coumarin-based probe, AzMC. The methylene blue method is not sensitive below 10 
!M and therefore could not be used to further validate these results.21  
 5.3.3 Detection of hydrogen sulfide in crude oil. While hydrogen sulfide levels 
were readily detected in sour water, the detection of hydrogen sulfide in crude oil posed 
more challenging. First, crude oil has considerable background fluorescence, a result of 
many contaminating hydrocarbons. This obstacle is easily overcome by use of time-
resolved fluorescence studies as previously described. Second, crude oil has low light 
transmission, especially at wavelengths below 300 nm (Figure 5.6). Low wavelengths are 
absorbed by the oil sample, making it extremely difficult to excite a probe. Lastly, crude 
oil, understandably, is not readily soluble in aqueous solutions. The reduction of azide-
based probes by hydrogen sulfide, however, is a water dependent reaction, something 
difficult to reconcile within a crude oil sample.  
Using dioxane as a solvent for its ability to dissolve both oil and water, we began  































Figure 5.6 Uv/Vis spectra of 100 !L crude oils 1–5 obtained from the Tesoro 
Corporation Refinery in Salt Lake City, Utah.  
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presence of 5% crude oil #4. While a significant increase in signal was seen in dioxane 
alone, the addition of oil decreased this signal drastically (Figure 5.7). We therefore opted 
to change our focus to compound 1. Compared to compound 3, compound 1 has the 
advantage of a higher excitation wavelength and is compatible with industrial oil 
samples, although it is not as sensitive in buffer. We theorized that this compound would 
prove more useful in samples with a high background absorbance and fluorescence. 
Indeed, a significant increase was seen in the presence of crude oil #4 (Figure 5.7) as a 
result of the higher excitation wavelength. In fact, compound 1 was able to detect added 
NaHS in the darkest crude oil samples, oils #1–3.  
After validating the usefulness of compound 1 in crude oil, we also tested the 
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Figure 5.7 Lanthanide complexes as H2S probes in crude oil. Left, compound 1 in the 
presence (solid) and absence (open) of oil # 4, with (red/pink) and without 
(black/grey) sulfide. Right panel, repeated with compound 3. A larger concentration of 
sulfide was needed.  
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found the range to be similar to that of compound 3 in buffer; namely, additional NaHS 
was detected from 50–300 !M (Figure 5.8). 
 
5.4 Results and Discussion of Colorimetric Hydrogen Sulfide Probes 
 As a complement to the fluorescent probes, a colorimetric hydrogen sulfide- 
selective probe was also desired. Theoretically, a probe with a strong visual response 
would have use not only in industrial laboratories but also to wider communities. While 
only specialists possess the proper instrumentation to detect hydrogen sulfide via a 
fluorescent signal, a visual change, for example from colorless to pink, can be readily 
detected by the majority of the population.  Such probes could be used to detect hydrogen 
sulfide contaminating ground or drinking water, or they could have use in the 
petrochemical industry as part of a two-phase assay. To this end, we have prepared the 
azide-derivative of aniline yellow, 4-azidoazobenzene (Figure 5.9), as a potential 


























Figure 5.8 NaHS concentration dependence of 10 !M compound 1 in the presence of 


















4-Azidoazobenzene was synthesized in an analogous manner to AzMC and 
AzCC. When dissolved in buffer (with the aid of DMSO), 4-azidoazobenzene is pale 
yellow in color; however, addition of millimolar concentrations of NaHS results in the 
formation of a bright yellow solution. The absorbance spectra of this solution is identical 
to that of the parent 4-aminoazobenzene (aniline yellow) (Figure 5.9). Additionally, the 
yellow color shows a dose-dependent response to NaHS. While not as sensitive as the 
fluorescent probes or the colorimetric assay methylene blue, 4-azidoazobenzene is an 
example of a simple, colorimetric assay for hydrogen sulfide. It provides a rapid, visual 
 
Figure 5.9 Studies of 7-Azidoazobenzene. a) Aniline yellow is produced by reduction 
of 7-Azidoazobenzene with NaHS. b) Absorbance spectra of 7-azidoazobenzene and 
aniline yellow. Aniline yellow does not react with NaHS while the azide reacts to form 
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readout and does not require the addition of multiple, freshly prepared reagents, as in the 
methylene blue assay. In the future this approach could be optimized for sensitivity.  
 
5.5 Conclusion 
In conclusion, we have described a series of new and previously reported 
lanthanide complexes that exhibit H2S-sensitive fluorescence. These complexes have 
significant utility in measuring H2S levels in samples from the petroleum industry. In 
particular, probe 3 has a detection limit of 250 nM NaHS in aqueous solutions, making it 
superior to both the methylene blue assay (with a detection limit around 10 !M H2S)21 
and the industry standard ion selective electrode protocol (detection limit of 1.2 !M) in 
terms of sensitivity. Probe 1, while less sensitive than probe 3, has the advantage of a 
higher excitation wavelength and could be optimized for use in monitoring sulfide levels 
in crude oil samples. Finally, 4-azidoazobenze is an early example of a colorimetric 
hydrogen sulfide-sensitive probe.  
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INHIBITION OF THE LYMPHOID TYROSINE PHOSPHATASE:  
THE EFFECT OF ZINC(II) IONS AND CHELATING  




A 96-member chelator fragment library (CFL-1.1) was screened to identify 
inhibitors of the lymphoid tyrosine phosphatase in the absence and presence of zinc 
acetate. Fragments that inhibit LYP activity more potently in the presence of zinc, 
fragments that rescue LYP activity in the presence of inhibitory concentrations of zinc, 
and fragments that inhibit LYP activity independent of zinc concentration were 
identified. Of these, 1,2-dihydroxynaphthalene was the most potent inhibitor with an IC50 
value of 2.52 ±0.06 !M after 2 h of incubation. LYP inhibition by 1,2-dihydroxy-
naphthalene was very similar to inhibition by 1,2-naphthoquinone (IC50 = 1.10 ±0.03), 
indicating that the oxidized quinone species is likely the active inhibitor. The inhibition 
was time-dependent, consistent with covalent modification of the enzyme.  
 
                                                
* This chapter is an adaptation of work accepted for publication. 




The protein tyrosine phosphatases (PTPs) are a family of signaling enzymes that 
play critical roles in human health. For example, aberrant PTP activity has been 
implicated in diseases as diverse as cancer, metabolic disorders, and autoimmunity.1–3 
Reliant on a nucleophilic cysteine residue for activity, the PTPs are also susceptible to 
inhibition by heavy metals4 and oxidation.5,6 Because the PTPs play such instrumental 
roles in human biology, there is great interest in developing inhibitors that could serve as 
chemical probes for dissecting the biological roles of the PTPs as well as potential lead 
compounds for therapeutic development.2,7,8  
One PTP of particular therapeutic interest is the lymphoid tyrosine phosphatase  
 
(LYP).9 LYP serves as a negative regulator of early T cell receptor signaling and has  
 
been implicated in the development of autoimmunity.10–12 Based on the known  
 
susceptibility of LYP to metal ions,4 oxidizing agents,5,6 and phosphotyrosine mimetic  
 
compounds such as salicylic acids,13–16 we decided to undertake a small-scale, fragment- 
 
based screen to identify metal binding fragments that inhibit LYP activity either alone or  
 
in complex with metal ions. The chelator fragment library used in this work, CFL-1.1  
 
(Figure A.1), incorporates a variety of metal-binding motifs in a total of 96 fragments.17  
 
Included in this library are phosphotyrosine mimetic moieties such as salicylic acids and  
 
picolinic acids and redox active fragments including catechols.  
 
A.3 Materials and Methods 
A.3.1 General considerations. All chemicals were purchased from commercial 


























































































































































































































































































































































































































































































































































































































were collected on a Varian 400 MHz NMR spectrometer. Chemical shifts were measured 
in parts per million referenced to internal standard (CH3)4Si = 0.00ppm. Fluorescence and 
UV/Vis were collected on a Molecular Devices Spectra Max M5. The catalytic domain of 
the lymphoid tyrosine phosphatase (LYP) was expressed and purified as previously 
described.18,19 
A.3.2 Zinc curves. All studies were carried out in 94 µl buffer (50 mM Bis Tris, 
100 mM NaCl, 0.01% Brij 35, pH 6.5) and 6 µl DMSO, which was used to dissolve the 
DiFMUP. The final probe concentration was 1.5 µM, and the final LYP concentration in 
each assay well was 5 nM. A 50 nM solution of LYP was activated with 1 mM TCEP for 
30 min on ice prior to use, activating a new aliquot of LYP prior to each experiment. The 
activated enzyme was incubated with zinc for 30 min at 25 °C before DiFMUP was 
added to initiate the reaction.  
A.3.3 Library screen. As with the zinc curves, all studies were carried out in 94 µl 
buffer (50 mM Bis Tris, 100 mM NaCl, 0.01% Brij 35, pH 6.5) and 6 µl DMSO, which 
was used to dissolve both the DiFMUP and the compounds. The final probe 
concentration was 1.5 µM, the final LYP concentration was 5 nM, and the final 
concentration of each library compound was 50 !M. As above, LYP was preactivated 
with TCEP prior to use. The compound, LYP, and zinc (if using) were incubated for 30 
min at 25 °C before starting the reaction with the addition of DiFMUP.  
A.3.4 Time-dependent inhibition of LYP by 1,2-dihyrdoxynaphthalene. The total 
DMSO concentration was held at 6%. In 100 !L total reaction volume (buffer: 50 mM 
Bis-Tris, 100mM NaCl, 0.01% Brij 35, 2mM EDTA, pH 6.5) 1,2-Dihyroxy-naphthalene 
was mixed with buffer with LYP progressively over 2 hours. The LYP was activated as 
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described and stored on ice. Immediately after the last addition (incubation time = “0 
min.”), DiFMUP was added to start the experiment.  
A.3.5 Selectivity of 1,2-Dihydroxynaphthalene for LYP over PTP1B, CD45, and 
YOP. LYP, PTP1B, YOP and CD45 were activated and used as described above and all  
used at a final concentration of 5 nM in 50 mM Bis-Tris, 100 mM NaCl, 0.01% Brij 35, 2  
 
mM EDTA, pH 6.5 buffer. 
 
A.4 Discussion of Results 
Initial investigations into the effect of zinc(II) on LYP activity under our standard 
assay conditions demonstrated that zinc is an effective inhibitor of LYP, with complete 
inhibition achieved in the presence of 100 !M zinc(II) acetate. This is not surprising, as 
thiophilic metal ions have been shown to act as competitive, pseudo-irreversible 
inhibitors of PTP activity, interacting with the catalytic cysteine residue.4,20–22 As shown 
in Figure A.2, in the presence of 40 !M of zinc acetate, the LYP activity was reduced to 
20% of the control, facilitating the identification of chelators that may rescue zinc-
mediated enzyme inhibition by binding to and removing the zinc from the enzyme active 
site. At 5 !M zinc acetate, the activity of LYP was reduced to 80% of the control, 
providing a useful starting point from which to identify chelators that may act 
synergistically with zinc to inhibit LYP activity. Using the information from the initial 
dose-response data with zinc acetate, three separate screens of the fragment library CFL-
1.1 were carried out: (1) in the presence of 40 !M zinc acetate to identify chelators 
capable of removing zinc from the active site of LYP and rescuing the enzyme from zinc-














compounds that display enhanced inhibition in the presence of zinc, and (3) in the 
absence of zinc in order to identify fragments capable of inhibiting LYP activity on their 
own.  
  As indicated in Figure A.3, di-(2-picolyl)-amine (3g), 5-chloro-8-quinolol (12b), 
and 2,6-pyridine dicarboxylic acid (8a) had little effect on enzymatic activity alone, but 
were each capable of rescuing the enzyme from zinc-mediated inhibition. These 
compounds are all known zinc chelators, and their ability to restore enzyme activity in 
the presence of zinc is consistent with the hypothesis that they may sequester zinc, 
removing it from the enzyme active site. The observation that the chelators are able to 
activate LYP slightly in the absence of added zinc is consistent with the sensitivity of the  


















Figure A.2. Inhibition of LYP activity by zinc acetate. Enzyme activity (defined as 
100% in the absence of Zn) decreases in a dose dependent manner as Zn(OAc)2 is 
added, with complete inhibition achieved at 100 !M added Zn(II). Inset shows the 




































usually carried out in a buffer containing EDTA to avoid this problem.23 It appears that, 
under the conditions of this assay, approximately two equivalents of each chelator 
(relative to zinc) are required to restore full activity.  
 A handful of compounds showed the potential for chelator-enhanced inhibition in 
the presence of 5 !M zinc acetate in our initial screen. Of these, only compound 5g (2-
hydroxy-1,4-naphthoquinone) showed consistent concentration-dependent inhibition of  
LYP in the presence of zinc (Figure A.4) in follow-up studies. The interpretation of these 
results is ambiguous because 2-hydroxy-1,4-naphthoquinone is a Michael acceptor.  
 
Figure A.3. Compounds 3g, 12b, and 8a have little effect on LYP activity on their own 
(open circles) but are all capable of restoring LYP activity in the presence of 40 !M 
zinc acetate (solid circles). Two equiv of chelator (80 !M) is sufficient to restore 


















































Similar compounds have been shown to form pseudo-irreversible adducts with the 
catalytic cysteine residue.24 Indeed, in the absence of zinc, compound 5g showed time-
dependent inhibition, with essentially no inhibition at the initial time point but an IC50 
value of 5.6 ±0.3 !M after 2 h of incubation. In the presence of zinc, there appears to be 
an additive effect in the inhibition of LYP by compound 5g (Figure A.4c).  
 The most potent hit from CFL-1.1 was compound 1h, 1,2-dihydroxynaphthalene. 
Compound 1h was also a time-dependent inhibitor of LYP activity, with an IC50 of 2.52 
±0.06 !M after 2 h of incubation  (Figure A.5). Compounds related to 1,2-dihydroxy-
naphthalene have been reported as PTP inhibitors previously, although it is likely the 
oxidized version of this compound that is active.25 In the presence of oxygen, 1h is 
readily oxidized to 1,2-naphthoquinone, an oxidant that has been reported to inhibit PTP  
b) a) 
 
Figure A.4. Inhibition of LYP by compound 5g. a) Compound 5g inhibits LYP 
activity more potently in the presence of zinc (solid circles) than in the absence of 
zinc (open circles). b) Compound 5g is a time-dependent inhibitor of LYP activity, 
showing increased inhibition as incubation time increases from 0 min (open circles) 
to 30 min (solid circles) to 60 min (triangles) and finally 120 min (squares). c) 
Inhibition of LYP by compound 5g in the presence of increasing amounts of zinc: 0 
























































activity.26 Indeed, 1,2-naphthoquinone shows very similar activity against LYP (Figure 
A.5), with an IC50 value of 1.10 ±0.03 !M after 2 h of incubation. As mentioned 
previously, similar compounds have been shown to form pseudo-irreversible adducts 
with the catalytic cysteine residue of the PTPs.24 However, 1,4-naphthoquinone 
derivatives have also been reported as selective allosteric inhibitors of PTP activity, 
acting through a non-redox-mediated mechanism.27 Interestingly, compound 1h has 
modest selectivity for LYP over PTP1B, CD45, and YopH (Figure A.6). This selectivity 
is not dramatic, but could serve as the starting point for building a more potent and 
selective LYP inhibitor.  
 
A.5 Conclusion 
From a library of 96 metal-binding fragments, we have identified a series of 














Figure A.5. Compound 1h (left panel) and 1,2-naphthoquinone (right panel) inhibit 
LYP activity in a time-dependent manner, showing increased inhibition as 
incubation time increases from 0 min (open circles) to 30 min (solid circles) to 60 

























the naphthoquinones 5g and 1h, which displayed time-dependent LYP inhibition 
consistent with covalent adduct. The 1,2-dihydroxynaphthalene scaffold has modest 
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